Induction of thyroid iodide-handling gene expression in human cancers

ABSTRACT

Dual suppression of the MAP kinase and PI3K/Akt pathways showed synergistic or greatly enhanced anti-melanoma cell effects, compared to suppression of a single pathway, including the inhibition of cell proliferation, transformation and invasion, induction of G 0 /G 1  cell cycle arrest and, importantly, cell apoptosis. Remarkably, suppression of either pathway induces the expression of thyroid iodide-handling genes and dual suppression of the two pathways synergistically and robustly induces expression of these genes, accompanied by uptake of radioiodine in the cells. These genes include sodium/iodide symporter, thyroid-stimulating hormone receptor, thyroglobulin, thyroperoxidase, pendrin gene, thyroid transcription factors (e.g., TTF-1, TTF-2, PAX8) and other thyroid genes. Targeting major signaling pathways, such as the MAP kinase and PI3K/Akt pathways, for potent cell death, optionally coupled with induction of thyroid gene expression for adjunct radioiodine ablation therapy may be used for many human cancers, both thyroid and non-thyroid.

STATEMENT OF GOVERNMENTAL INTEREST

This invention was made with government support under grant CA113507,awarded by the National Institutes of Health. The government has certainrights in the invention.

TECHNICAL FIELD OF THE INVENTION

This invention is related to the area of cancer. In particular, itrelates to cancer treatment.

BACKGROUND OF THE INVENTION

Cancer is a major cause of human death. There is currently no cure formany types of human cancers. Many cancers are very aggressive with ahigh mortality and some have an increasing incidence in recent years.For example, melanoma is a common skin cancer and recent decades haveseen a markedly increase in its incidence worldwide (Jemal A, Devesa SS, Hartge P, Tucker M A. Recent trends in cutaneous melanoma incidenceamong whites in the United States. J Natl Cancer Inst 2001; 93:678-83;Lasithiotakis K G, Leiter U, Gorkievicz R, et al. The incidence andmortality of cutaneous melanoma in Southern Germany: trends by anatomicsite and pathologic characteristics, 1976 to 2003. Cancer 2006;107:1331-9; Ries L A G, Melbert D, Krapcho M, et al. (eds). SEER CancerStatistics Review, 1975-2005, National Cancer Institute. Bethesda, Md.,http://seer.cancer.gov/csr/1975_2005/, based on November 2007 SEER datasubmission, posted to the SEER web site, 2008). In the United Statesalone, 62,480 new cases and 8,420 deaths from melanoma were estimatedfor the year of 2008 (Ries, supra). Although early-stage disease iscurable through surgical excision, advanced metastatic melanoma isresistant to current treatments, with a rapidly progressive course andhigh mortality rate (Flaherty Ky. Chemotherapy and targeted therapycombinations in advanced melanoma. Clin Cancer Res 2006; 12:2366s-70s;Tawbi H A, Kirkwood J M. Management of metastatic melanoma. Semin Oncol2007; 34:532-45).

A major effort in melanoma research has thus been to identify noveltreatment strategies targeting major molecular pathways, particularlythe Ras→Raf→MEK→MAP kinase/ERK (MAPK) and PI3K/Akt signaling pathways,which are commonly over-activated by genetic alterations, such as theBRAF mutations in the MAPK pathway (Davies H, Bignell G R, Cox C, et al.Mutations of the BRAF gene in human cancer. Nature 2002; 417:949-54) andthe PIK3CA amplification and PTEN mutations in the PI3K/Akt pathway (WuH, Goel V, Haluska F G. PTEN signaling pathways in melanoma. Oncogene2003 22:3113-22; Curtin J A, Fridlyand J, Kageshita T, et al. Distinctsets of genetic alterations in melanoma. N Engl J Med 2005; 353:2135-47;Marquette A, Bagot M, Bensussan A, Dumaz N. Recent discoveries in thegenetics of melanoma and their therapeutic implications. Arch ImmunolTher Exp (Warsz) 2007; 55:363-72). These two pathways play a fundamentalrole in the pathogenesis and progression of melanoma and are thereforeimportant therapeutic targets for this cancer (Satyamoorthy K, Li G,Gerrero M R, et al. Constitutive mitogen-activated protein kinaseactivation in melanoma is mediated by both BRAF mutations and autocrinegrowth factor stimulation. Cancer Res 2003; 63:756-9; Stahl J M, SharmaA, Cheung M, et al. Deregulated Akt3 activity promotes development ofmalignant melanoma. Cancer Res 2004; 64:7002-10; Dai D L, Martinka M, LiG. Prognostic significance of activated Akt expression in melanoma: aclinicopathologic study of 292 cases. J Clin Oncol 2005; 23:1473-82;Meier F, Schittek B, Busch S, et al. The RAS/RAF/MEK/ERK and PI3K/AKTsignaling pathways present molecular targets for the effective treatmentof advanced melanoma. Front Biosci 2005; 10:2986-3001; Meier F, Busch S,Lasithiotakis K, et al. Combined targeting of MAPK and AKT signallingpathways is a promising strategy for melanoma treatment. Br J Dermatol2007; 156:1204-13; Kwong L, Chin L, Wagner S N. Growth factors andoncogenes as targets in melanoma: lost in translation? Adv Dermatol2007; 23:99-129).

Radioiodine therapy based on the sodium/iodide symporter (NIS) genetransfer has been widely investigated as a potential therapeuticstrategy for extrathyroidal malignancies (Faivre J, Clerc J, Gérolami R,et al. Long-term radioiodine retention and regression of liver cancerafter sodium iodide symporter gene transfer in Wistar rats. Cancer Res2004; 64:8045-51; Dwyer R M, Bergert E R, O'connor M K, et al. In vivoradioiodide imaging and treatment of breast cancer xenografts afterMUC1-driven expression of the sodium iodide symporter. Clin Cancer Res2005; 11:1483-9; Riesco-Eizaguirre G, Santisteban P. A perspective viewof sodium iodide symporter research and its clinical implications. Eur JEndocrinol 2006; 155:495-512; Schipper M L, Riese C G, Seitz S, et al.Efficacy of 99mTc pertechnetate and 131I radioisotope therapy insodium/iodide symporter (NIS)-expressing neuroendocrine tumors in vivo.Eur J Nucl Med Mol Imaging 2007; 34:638-50; Willhauck M J, Sharif SamaniB R, Klutz K, et al. Alpha-fetoprotein promoter-targeted sodium iodidesymporter gene therapy of hepatocellular carcinoma. Gene Ther 2008;15:214-23). NIS is normally expressed in the basal membrane offollicular thyroid cells, which transports iodide from blood stream intothe cell for the biosynthesis of thyroid hormone (Riesco-Eizaguirre,supra; Nilsson M. Iodide handling by the thyroid epithelial cell. ExpClin Endocrinol Diabetes 2001; 109:13-17). This process also involvesseveral other key molecules, including thyroglobulin (Tg), whichincorporates iodide through organification that involves thyroperoxidase(TPO). Thyroid transcription factor 1 (TTF1 or TITF1) and 2 (TTF2 orFOXE1) and PAX8 are involved in the regulation of these genes.Expression of many of these iodide-handling genes in the thyroid cell isup-regulated by the thyroid-stimulating hormone (TSH), which acts on theTSH receptor (TSHR) in the thyroid cell membrane. This is the molecularbasis for the commonly used radioiodide ablation therapy for thyroidcancer, which is clinically facilitated by increasing the level of TSHin the blood of the patient either through thyroid hormone withdrawal oradministration of recombinant human TSH (Mian C, Lacroix L, Bidart J.-M,Caillou B, Filetti S, Schlumberger M. Sodium/iodide symporter in thyroidcancer. Exp Clin Endocrinol Diabetes 2001; 109: 47-51; Duntas L H,Cooper D S. Review on the occasion of a decade of recombinant human TSH:prospects and novel uses. Thyroid 2008; 18(5):509-16). In papillarythyroid cancer (PTC), BRAF mutation (and hence activation of the MAPKpathway) was associated with decreased radioiodine avidity (Xing M,Westra W H, Tufano R P, et al. BRAF mutation predicts a poorer clinicalprognosis for papillary thyroid cancer. J Clin Endocrinol Metab 2005;90:6373-9; Riesco-Eizaguirre G, Gutierrez-Martinez P, Garcia-Cabezas MA, Nistal M, Santisteban P. The oncogene BRAF V600E is associated with ahigh risk of recurrence and less differentiated papillary thyroidcarcinoma due to the impairment of Na+/I− targeting to the membrane.Endocr Relat Cancer 2006; 13:257-69; Mian C, Barollo S, Pennelli G, etal. Molecular characteristics in papillary thyroid cancers (PTCs) withno (131)I uptake. Clin Endocrinol 2008; 68:108-16), which can beexplained by BRAF mutation-associated silencing of thyroidiodide-handling genes, such as NIS (Riesco-Eizaguirre G, Santisteban P,supra; Durante C, Puxeddu E, Ferretti E, et al. BRAF mutations inpapillary thyroid carcinomas inhibit genes involved in iodinemetabolism. J Clin Endocrinol Metab 2007; 92:2840-3), Tg (Durante,supra), and TPO (Mian, supra; Durante, supra; Giordano T J, Kuick R,Thomas D G, et al. Molecular classification of papillary thyroidcarcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific geneexpression profiles discovered by DNA microarray analysis. Oncogene2005; 24:6646-56; Di Cristofaro J, Silvy M, Lanteaume A, Marcy M,Carayon P, De Micco C. Expression of tpo mRNA in thyroid tumors:quantitative PCR analysis and correlation with alterations of ret, Braf,ras and pax8 genes. Endocr Relat Cancer 2006; 13:485-95). Severalprevious studies also demonstrated involvement of the PI3K/Akt pathwayin the regulation of thyroid iodide-handling genes. For example,expression of a mutant Ras that selectively stimulated the PI3K/Aktpathway markedly decreased TSH-induced NIS expression (Cass L A,Meinkoth J L. Ras signaling through PI3K confers hormone-independentproliferation that is compatible with differentiation. Oncogene. 2000;19:924-32) and IGF-I could inhibit cAMP-induced NIS expression throughactivating the PI3K/Akt pathway (Garcia B, Santisteban P. PI3K isinvolved in the IGF-I inhibition of TSH-induced sodium/iodide symportergene expression. Mol Endocrinol 2002; 16:342-52) in thyroid cells.

In recent clinical trials on various human cancers, including melanoma,targeting an individual pathway, such as the MAPK pathway or thePI3K/Akt pathway, or use of a single agent generally failed to showsignificant clinical responses (Marquette, supra; Kwong, supra; Friday BB and Adjei A A. Advances in targeting the Ras/Raf/MEK/Erkmitogen-activated protein kinase cascade with MEK inhibitors for cancertherapy. Clin Cancer Res 2008; 14:342-6). A recent study showed commonexpression of TSHR in melanoma cells, but no or little expression inbenign skin lesions (Ellerhorst J A, Sendi-Naderi A, Johnson M K, CookeC P, Dang S M, Diwan A H. Human melanoma cells express functionalreceptors for thyroid-stimulating hormone. Endocr Relat Cancer 2006;13:1269-77), raising the possibility that other thyroid iodide-handlinggenes might also be expressible in melanoma cells.

There is a continuing need in the art to develop more effectivetreatments for human cancers.

SUMMARY OF THE INVENTION

According to one aspect of the invention a method is provided fortreating a human cancer in a patient. An inhibitor of a PI3K/Akt pathwayprotein or its expression is administered to the patient. And aninhibitor of a MAP kinase pathway protein or its expression isadministered to the patient. The inhibitors are administered insufficient amounts to induce expression of one or more iodide-handlinggenes in the human cancer.

According to another aspect of the invention a method is provided fortreating a human cancer in a patient. An inhibitor of a PI3K/Akt pathwayprotein or its expression or of a MAP kinase pathway protein or itsexpression is administered to the patient in sufficient amounts toinduce expression of one or more iodide-handling genes in the humancancer. And radioiodine is administered to the patient.

Yet another aspect of the invention provides a method for treating amelanoma or a thyroid cancer in a human. An inhibitor of a PI3K/Aktpathway protein or its expression and an inhibitor of a MAP kinasepathway protein or its expression are administered to the patient insufficient amounts to induce expression of one or more iodide-handlinggenes in the melanoma or thyroid cancer. And radioiodine is administeredto the human.

A further aspect of the invention is a kit. The kit comprises in adivided or undivided container at least two of the following therapeuticagents: an inhibitor of a PI3K/Akt pathway protein or its expression, aninhibitor of a MAP kinase pathway protein or its expression, andradioiodine.

These and other embodiments which will be apparent to those of skill inthe art upon reading the specification provide the art with new ways toeffectively treat human cancers.

BRIEF DESCRIPTION OF THE DRAWINGS

FIGS. 1A-1C Effects of suppression of the MAPK and PI3K/Akt pathways byspecific inhibitors on NPA cells. FIG. 1A) Inhibition of ERK and Aktphosphorylation by suppression of MAPK and PI3K/Akt pathways using theMEK-specific inhibitor U0126 and the Akt-specific inhibitor Akti IV,respectively. NPA cells were treated with U0126 at 10 μM, or with AktiIV at 0.5 μM for 30 h. Cells were lysed for Western blotting assay. Theactivities of MAPK and PI3K/Akt pathways were reflected by the level ofphosphorylated ERK and Akt detected with specific anti-phosphorylatedERK (p-ERK) and anti-phosphorylated Akt (p-Akt) antibodies.Immunoblotting with antibody against β-actin was used for qualitycontrol. FIG. 1B) Inhibition of cell proliferation by suppression ofMAPK and PI3K/Akt pathways achieved with U0126 and Akti IV individuallyor in combination (U+A) as indicated. MTT assay was performed toevaluate cell proliferation over a 5-day course of treatment with U0126and Akti IV. NPA cells were treated with 4 μM U0126 and 0.2 μM Akti IV,respectively—lower concentrations than those in FIG. 1A) were used forthe two inhibitors in order to examine their additive/synergist effects.FIG. 1C) Expression of thyroid genes by dual suppression of MAPK andPI3K/Akt pathways using U0126 and Akti IV. For expression analysis ofthyroid genes (NIS, TSHR, Tg, TPO, FOXE1, and TTF1), total RNA wasisolated and RT-PCR was performed 30 h after cells were treated withU0126 and Akti IV individually or combination at the concentrations usedin FIG. 1A).

FIG. 2A-2B Effect of TSH stimulation on expression of thyroid genesmediated by suppressing MAPK and PI3K/Akt pathways, individually or incombination, in melanoma cells. Melanoma cells, as indicated, weretreated with specific inhibitors (U0126 and Akti IV) as described inFIGS. 1A-1C. Before RNA was extracted, cells were treated with 40 mU/mlTSHb for 6 h. Details are described in the Materials and Methods. Dataare presented as the mean±SD of values from three assays. In comparisonwith control, *, P<0.05; **, P<0.01.

FIG. 3A-3C Effects of stable siRNA knockdown of BRAF and Akt-1/2,individually or dually, on cell proliferation and colony formation. FIG.3A) NPA cells were infected with lentivirus expressing BRAF or Akt-1/2siRNAs or both and stable populations were selected with 2 μg/mlpuromycin. The empty vector was used as the control. After a 2-weekselection, cells were lysed and immunoblotted with BRAF, Akt-1 and Akt-2antibodies. The antibody against β-actin was used for quality control ofWestern blotting. FIG. 3B) Proliferation rate of NPA cells stablytransfected with various siRNA constructs as described in FIG. 3A) wasmeasured with MTT assay daily over a 5-day course. Results are expressedas means±SD of three independent experiments. FIG. 3C) Representativeresults of colony formation in soft agar of thyroid cancer cells withstable transfections with different siRNA constructs, including emptyvector (vector), BRAF siRNA (BRAF KD), Akt-1/2 siRNA (Akt-1/2 KD), andcombination of Akt-1/2 and BRAF siRNA (BRAF+Akt-1/2 KD). Data representmeans±SD of three independent experiments. KD, knockdown (same as in allother Figures).

FIGS. 4A and 4B. Effects of stable siRNA knockdown of BRAF and Akt-1/2,individually or dually, on the invasion of NPA cells. Invading rate ofcells stably transfected with specific siRNAs constructs to knock downBRAF and Akt-1/2, individually or dually, as described in FIGS. 3A-3Cwas measured using Matrigel-coated transwell cell culture chambers. FIG.4A) Shown are representative results of invasive NPA cells. FIG. 4B) Thebar graphs, corresponding to (FIG. 4A), show means±SD of the numbers ofinvading cells from three independent experiments.

FIG. 5A-5B. Effects of siRNA knockdown of BRAF and Akt-1/2, individuallyor dually, on G₀/G₁ cell cycle arrest and apoptosis of NPA cells. NPAcells were transiently transfected with specific siRNAs to knock downBRAF and Akt-1/2, individually or dually as indicated. After a 4-dayculture, DNA content (FIG. 5A) was measured by flow cytometry todetermine cell cycle fractions. The fraction of apoptotic cells (sub-G₀)is indicated (FIG. 5A). Cell apoptosis (FIG. 5B) was measured by AnnexinV staining and flow cytometry. The right lower quadrant of each plotcontains early apoptotic cells, whereas the right upper quadrantcontains late apoptotic cells. Details are described in the Materialsand Methods.

FIG. 6A-6D. Effects of suppression of MAPK and PI3K/Akt pathways,individually or in combination, on the expression of NIS and radioiodineuptake in NPA cells. FIG. 6A) NPA cells were stably transfected withspecific siRNAs to knock down BRAF and Akt-1/2, individually or duallyas described in FIG. 3. After a serum starvation for 24 h, total RNA wasisolated for expression analysis for the indicated thyroidiodide-metabolizing genes. RT-PCR analysis was performed for theexpression of NIS in NPA cells. FIG. 6B) Flow cytometric measurement ofNIS protein expression. NPA cells were treated with specific inhibitors(upper panel) as described in FIG. 1 or stably transfected with specificsiRNAs to knock down BRAF and Akt-1/2, individually or in combination asdescribed in FIG. 3 (lower panel). NIS protein levels were measured byflow cytometry. The blue frames indicate the cells expressing NISprotein, including dead (right upper quadrant; positive for both 7-AADand NIS) and living (right lower quadrant, positive only for NIS) cells.FIG. 6C) Immunofluorescent localization of NIS. After a 30-h combinedtreatment with both U0126 and Akti IV (as in FIG. 6B), cells wereanalyzed by immunofluorescent microscopy using anti-NIS and FITC-coupledsecondary antibody and double immunofluorescence with the red colorrepresenting 7-AAD nuclear staining and the green color representing NISexpression and localization. Cells marked with dash circles are intactliving cells that do not have 7-AAD nuclear staining. NIS staining inthese cells represents NIS protein expression exclusively on the cellmembrane. Cells marked with solid circles show double colors, suggestingthat the cells were not intact and therefore both cell membrane NISstaining and 7-AAD nuclear staining occurred. The NIS expression is instriking contrast with the control cells which did not show any NISstaining even in the broken cells that showed nuclear staining (redcolor) with 7-ADD. FIG. 6D) In vitro radioiodide uptake. NPA cells weretreated with specific inhibitors or stably transfected with varioussiRNA constructs as indicated. Cells were subsequently incubated with 1μCi ¹²⁵I/0.5 ml/well on 12-well plates for 1 h. Cells were then washedand harvested for radioactivity measurement using a gamma-counter asdescribed in the Materials and Methods. Data are expressed as themean±SD of values from three assays. **, P<0.01, compared with controlor empty vector.

FIG. 7A-7C. Effects of suppression of the PI3K/Akt and MAP kinasepathways by specific inhibitors on thyroid cancer cells. FIG. 7A)Inhibition of Akt and ERK phosphorylation by suppression of PI3K/Akt andMAP kinase pathways using the Akt-specific inhibitor Akti IV and theMEK-specific inhibitor U0126, respectively. NPA and KAT10 cells weretreated with Akti IV at 0.5 and 2 μM, respectively, or with U0126 at 10μM for 30 h. Cells were lysed for Western blotting assay. The activitiesof PI3K/Akt and MAP kinase pathways were reflected by the level ofphosphorylated Akt and ERK detected with specific anti-phosphorylatedAkt (p-Akt) and anti-phosphorylated ERK (p-ERK) antibodies.Immunoblotting with antibody against β-actin was used for qualitycontrol. FIG. 7B) Inhibition of thyroid cancer cell proliferation bysuppression of PI3K/Akt and MAP kinase pathways achieved with Akti IVand U0126 individually or in combination (U+A) as indicated. MTT assaywas performed to evaluate cell proliferation over a 5-day course oftreatment with Akti IV and U0126. One μM Akti IV for KAT10 cells and 0.2μM Akti IV for NPA cells and 4 μM U0126 for both cells were used—lowerconcentrations than those in FIG. 7A) were used for the two inhibitorsin order to examine their additive/synergist effects. FIG. 7C)Synergistic re-expression of thyroid genes by dual suppression ofPI3K/Akt and MAP kinase pathways using Akti IV and U0126. For expressionanalysis of thyroid genes (Tg, TSHR, NIS, TTF-1, and TTF2), total RNAwas isolated and quantitative real-time PCR was performed 30 h aftercells were treated with Akti IV and U0126 individually or combination atthe concentrations used in FIG. 7A). The value for each gene representsthe mean of triplicate measurements.

FIG. 8A-8D. Effects of transient isoform-specific knockdown of Akt bysiRNA on proliferation and colony formation of thyroid cancer cellsadditionally transfected with or without specific siRNA for BRAF. FIG.8A) KAT10 cell clones stably transfected with BRAF-specific siRNA (cloneC9) and control scrambled siRNA (clone 2B2) were superinfected withshRNA vectors targeting Akt-1 or Akt-2. Empty vectors (V) were used ascontrols. Two different sets of siRNA sequences (A and B) for Akt-1 andAkt-2 were used as described in the Experimental Procedures. Cells werelysed and immunoblotted with Akt isoform- or BRAF-specific antibodies asindicated. Immunoblotting with antibody against β-actin was used forquality control of Western blotting. Set A of siRNA sequences were usedin the experiments in FIG. 8B, 8C, and 8D. FIG. 8B) Fluorescentmicroscopy of 2B2 and C9 cell clones superinfected with GFP-containingconstructs to knock down Akt-1 or Akt-2 (indicated as Akt-1 KD and Akt-2KD, respectively). Empty vectors were used as control. At two weeks ofcell culture, GFP expression was examined using a fluorescent microscope(Nikon Eclipse TE300, NY) to confirm the high efficiency and stabilityof transfection. FIG. 8C) Effect of Akt-1 or Akt-2 and BRAF knockdown oncell proliferation. 2B2 and C9 cell clones superinfected with emptyvector, Akt-1 or Akt-2 shRNA were grown in triplicates of culture forthe indicated days, with initial seeding of 800 cells per well. MTTassay was performed daily to evaluate cell proliferation (means±SD oftriplicate). FIG. 8D) Colony formation assays were performed to evaluateanchorage-independent growth of 2B2 and C9 cell clones aftersuperinfection with Akt-1 or Akt-2 siRNA. After culture in soft agar for3 wk, colonies were counted and photographed. A representativeexperiment of colony formation with various shRNA constructs ispresented with a corresponding bar graph (right panel) showing themean±SD of colony numbers from three independent experiments. KD,knockdown (same as in all other Figures).

FIG. 9A-9C. Effects of stable siRNA knockdown of Akt-1/2 and BRAF,individually or dually, on thyroid cancer cell proliferation and colonyformation. FIG. 9A) NPA and KAT10 cells were infected with lentivirusexpressing Akt-1/2 or BRAF siRNAs or both and stable populations wereselected with 2 μg/ml puromycin. Empty vector was used as control. Aftera 2-week selection, cells were lysed and immunoblotted with Akt-1,Akt-2, and BRAF antibodies. The antibody against β-actin was used forquality control of Western blotting. FIG. 9B) Proliferation rate ofthyroid cancer cells stably transfected with various siRNA constructs asdescribed for A) was measured with MTT assay daily over a 5-day course.Results are expressed as means±SD of three independent experiments. FIG.9C) Representative results of colony formation in soft agar of thyroidcancer cells with stable transfections with different siRNA constructs,including empty vector (a), Akt-1/2 siRNA (b), BRAF siRNA (c), andcombination of Akt-1/2 and BRAF siRNA (d). Data represent means±SD ofthree independent experiments.

FIG. 10A-10B. Effects of stable siRNA knockdown of Akt-1/2 and BRAF,individually or dually, on the invasion of thyroid cancer cells.Invading rate of cells stably transfected with specific siRNAsconstructs to knock down Akt-1/2 and BRAF, individually or dually, asdescribed in FIG. 3 was measured using Matrigel-coated transwell cellculture chambers. Shown are representative results of invasive NPA (FIG.10A) and KAT 10 (FIG. 10B) cells. The bar graphs in the right panels,corresponding to left panels, show means±SD of the numbers of invadingcells from three independent experiments.

FIG. 11A-11B. Effects of siRNA knockdown of Akt-1/2 and BRAF,individually or dually, on G0/G1 cell cycle arrest and apoptosis ofthyroid cancer cells. NPA (FIG. 11A) and KAT10 (B) cells weretransiently transfected with specific siRNAs to knock down Akt-1/2 andBRAF, individually or dually as indicated. After a 4-day culture, DNAcontent (FIG. 11A and FIG. 11B, upper panels) was measured by flowcytometry to determine cell cycle fractions. The fraction of apoptoticcells (sub-G0) is indicated (A, upper panel). Cell apoptosis (FIG. 11Aand FIG. 11B, lower panels) was measured by Annexin V staining and flowcytometry. The right lower quadrant of each plot contains earlyapoptotic cells, whereas the right upper quadrant contains lateapoptotic cells. Details are described in the Experimental Procedures.

FIG. 12A-12C. Effects of stable siRNA knockdown of Akt-1/2 and BRAF,individually or dually, on in vivo growth of thyroid cancer. KAT10 cellswere stably transfected with specific siRNAs to knock down Akt-1/2 andBRAF, individually or dually as described in FIG. 9. Cells were injectedsubcutaneously into the flank of nude mice (n=5 in each group), and theanimals were subsequently monitored for tumor growth. FIG. 12A) Timecourse of tumor growth over 3.5 weeks with stable knockdown of theindicated proteins. Tumor size was measured on the surface of the skin,and tumor volume was calculated as described in the ExperimentalProcedures. Each time point represents the mean ±SD of the valuesobtained from five mice in each group. FIG. 12B) Shown are the weightsof individual tumors surgically removed from mice in each group aftertheir sacrifice. **The P value was obtained by t-test for pairedcomparison with vector. FIG. 12C) Shown are representative images oftumor-bearing mice at 2 and 3.5 weeks and their tumors after surgicalremoval from mice.

FIG. 13A-13C. Effects of stable siRNA knockdown of Akt-1/2 and BRAF,individually or dually, on the expression of thyroid iodide-metabolizinggenes. NPA and KAT10 cells were stably transfected with specific siRNAsto knock down Akt-1/2 and BRAF, individually or dually as described inFIG. 9. After a serum starvation for 24 h, total RNA was isolated forexpression analysis for the indicated thyroid iodide-metabolizing genes.Quantitative real-time PCR analysis was performed for the expression ofthyroid genes, including Tg, TSHR, NIS, TTF1, and TTF2 in NPA (FIG. 13A)and KAT10 (FIG. 13B) cells. FIG. 13C) Regular RT-PCR analysis of NISexpression to confirm the results obtained by quantitative real-timePCR.

FIG. 14A-14C. Effects of suppression of PI3K/Akt and MAP kinasepathways, individually or in combination, on the expression of NISprotein and radioiodide uptake in thyroid cancer cells. FIG. 14A) Flowcytometric measurement of NIS protein expression. NPA and KAT10 cellswere treated with specific inhibitors (FIG. 14A, upper panel) asdescribed in FIG. 7D or stably transfected with specific siRNAs to knockdown Akt-1/2 and BRAF, individually or in combination as described inFIG. 9 (A, lower panel). NIS protein levels were measured by flowcytometry. The blue frames indicate the cells expressing NIS protein,including dead (right upper quadrant; positive for both 7-AAD and NIS)and living (right lower quadrant, positive only for NIS) cells. FIG.14B) Immunofluorescent localization of NIS. After a 30-h combinedtreatment with both Akti IV and U0126 (as in FIG. 14A), cells wereanalyzed by immunofluorescent microscopy using anti-NIS and FITC-coupledsecondary antibody and double immunofluorescence with the red colorrepresenting 7-AAD nuclear staining and the green color representing NISexpression and localization. Cells marked with dash circles are intactliving cells that do not have 7-AAD nuclear staining. NIS staining inthese cells represents NIS protein expression exclusively on the cellmembrane. Cells marked with solid circles show double colors, suggestingthat the cells were not intact and therefore NIS staining could be bothintracellular and on the cell membrane. In either type of cells, the NISexpression is in striking contrast with the control cells which did notshow any NIS staining even in the broken cells that showed nuclearstaining (red color) with 7-ADD. FIG. 14C) In vitro radioiodide uptake.NPA and KAT10 cells were treated with specific inhibitors or stablytransfected with various siRNA constructs as indicated. Cells weresubsequently incubated with 1 μCi Na125I/0.5 ml/well on 12-well platesfor 1 h. Cells were then washed and harvested for radioactivitymeasurement using a gamma-counter as described in the ExperimentalProcedures. Data are expressed as the mean±SD of values from threeassays. **, P<0.01, compared with control or empty vector.

DETAILED DESCRIPTION OF THE INVENTION

The inventors have developed methods of treating human cancers whichemploy inhibitors to suppress MAP kinase and PI3K/Akt pathways.Surprisingly, while suppression of individual pathways provides only acytostatic effect on cancer cells, suppression of both provides acytotoxic effect. Remarkably, use of such inhibitors has also been foundto induce expression of genes encoding iodide-handling proteins. As aconsequence of such induced expression, radioiodine can be administeredand its uptake, which is normally seen mainly in thyroid cells, can beused for ablation therapy in cells that previously expressed none orinsufficient amounts of such proteins. Such cells include thyroid cancercells that were previously refractory to radioiodine and non-thyroidcancer cells that were refractory to radioiodine.

Types of human cancers which may be treated as described here includeboth thyroid and non-thyroid cancers. In particular, the methods areuseful in cases of thyroid cancer that have become unable to take upiodide. These are often the least differentiated types of thyroidcancers, i.e., the poorly differentiated and the undifferentiated types,such as anaplastic carcinomas. In addition, even cell types thatnormally do not have the ability to take up iodide, i.e., non-thyroidcells, can become susceptible to therapy with radioiodide, by virtue ofthe induction of expression of the genes encoding iodide handlingproteins. Suitable cancers for treatment thus include without limitationsalivary cancer, lacrimal cancer, stomach cancer, colon cancer, livercancer, breast cancer, and other cancers. Even in the case where anormal cell type expresses some level of the iodide handling proteins,treatment according to the invention can enhance expression of theproteins. Additional tumor types that may be treated include, withoutlimitation, brain cancers, lymphoma, leukemia, sarcomas, pancreaticcancer, liver, cancer, and myeloma. Other types of cancer which may betreated include cancer of the bladder, rectum, kidney, lung (small celllung cancer, and non-small-cell lung cancer), esophagus, gall-bladder,ovary, cervix, thyroid, prostate, and skin (including squamous cellcarcinoma); tumors of mesenchymal origin (including fibrosarcoma andrhabdomyosarcoma, and other sarcomas, e.g., soft tissue and bone);tumors of the central and peripheral nervous system (includingastrocytoma, neuroblastoma, glioma and schwannomas); and other tumors(including melanoma, seminoma, teratocarcinoma, osteosarcoma, xenoderomapigmentosum, keratoctanthoma, thyroid follicular cancer and Kaposi'ssarcoma). Other cancers that can be treated with agents of the presentinvention include endometrial cancer, head and neck cancer,glioblastoma, malignant ascites, and other hematopoietic cancers.

The cancers that are to be treated may or may not have activatingmutations in the MAP kinase or PI3K/Akt pathways. Activating mutations,if present may be in any gene in the pathways, and may be due to pointmutation or rearrangement or amplification, as examples.

Agents that can be used to suppress major signaling pathways to inhibitcells and induce thyroid gene expression and radioiodine uptake in humancancers include, but are not limited to, the inhibitors of the MAPkinase pathways, e.g., MEK inhibitors, such as CI-1040, PD0325901,AZD6244, RDEA119, RDEA436; Raf inhibitors, such as PLX4720, BAY 43-9006(sorafenib); inhibitors of the PI3K/Akt pathway, e.g., Akt inhibitors,such as perifosine and triciribine; mTOR inhibitors, such astemsirolimus, everolimus; receptor tyrosine kinase inhibitors, e.g.,motesanib, axitinib, sunitinib; and inhibitors of other signalingpathways, such as the NF-kappa pathway. Individual members of thePI3K/Akt pathway are well known in the art and include: PIK3CA,PIK3D,PIK3B, Ras, and PTEN. Members of the MAP kinase pathway include receptortyrosine kinases, Grb-2, mSOS, Rsk1, BRAF, RET/PTC, Ras, MEK, and ERK.When two pathways are to be inhibited, two distinct inhibitors of twodistinct proteins can be used. Multiple inhibitors of each pathway mayalso be used, if desired. Certain inhibitors such as Ras inhibitors mayact on both pathways and these may also be used in the invention.

Agents for suppression of major signaling pathways can also inhibitexpression. Means of inhibition include siRNA, antisense RNA, antisenseRNA vectors, miRNA, and other means. Antisense constructs, antisenseoligonucleotides, RNA interference constructs, miRNA or siRNA duplex RNAmolecules can be used to interfere with expression of a desired pathwaymember protein. Typically at least 15, 17, 19, or 21 nucleotides of thecomplement of a desired pathway member protein mRNA sequence aresufficient for an antisense molecule. Typically at least 19, 21, 22, or23 nucleotides of a desired pathway member protein are sufficient for anRNA interference molecule. Preferably an RNA interference molecule willhave a 2 nucleotide 3′ overhang. If the RNA interference molecule isexpressed in a cell from a construct, for example from a hairpinmolecule or from an inverted repeat of the desired pathway memberprotein sequence, then the endogenous cellular machinery will create theoverhangs. siRNA molecules can be prepared by chemical synthesis, invitro transcription, or digestion of long dsRNA by Rnase III or Dicer.These can be introduced into cells by transfection, electroporation, orother methods known in the art. See Hannon, G J, 2002, RNA Interference,Nature 418: 244-251; Bernstein E et al., 2002, The rest is silence. RNA7: 1509-1521; Hutvagner Get al., RNAi: Nature abhors a double-strand.Curr. Opin. Genetics & Development 12: 225-232; Brummelkamp, 2002, Asystem for stable expression of short interfering RNAs in mammaliancells. Science 296: 550-553; Lee N S, Dohjima T, Bauer G, Li H, Li M-J,Ehsani A, Salvaterra P, and Rossi J. (2002). Expression of smallinterfering RNAs targeted against HIV-1 rev transcripts in human cells.Nature Biotechnol. 20:500-505; Miyagishi M, and Taira K. (2002).U6-promoter-driven siRNAs with four uridine 3′ overhangs efficientlysuppress targeted gene expression in mammalian cells. Nature Biotechnol.20:497-500; Paddison P J, Caudy A A, Bernstein E, Hannon G J, andConklin D S. (2002). Short hairpin RNAs (shRNAs) inducesequence-specific silencing in mammalian cells. Genes & Dev. 16:948-958;Paul C P, Good P D, Winer I, and Engelke D R. (2002). Effectiveexpression of small interfering RNA in human cells. Nature Biotechnol.20:505-508; Sui G, Soohoo C, Affar E-B, Gay F, Shi Y, Forrester W C, andShi Y. (2002). A DNA vector-based RNAi technology to suppress geneexpression in mammalian cells. Proc. Natl. Acad. Sci. USA99(6):5515-5520; Yu J-Y, DeRuiter S L, and Turner D L. (2002). RNAinterference by expression of short-interfering RNAs and hairpin RNAs inmammalian cells. Proc. Natl. Acad. Sci. USA 99(9):6047-6052.

Antisense or RNA interference molecules can be delivered in vitro tocells or in vivo, e.g., to tumors of a mammal. Typical delivery meansknown in the art can be used. For example, delivery to a tumor can beaccomplished by intratumoral injections. Other modes of delivery can beused without limitation, including: intravenous, intramuscular,intraperitoneal, intraarterial, local delivery during surgery,endoscopic, subcutaneous, and per os. In a mouse model, the antisense orRNA interference can be adminstered to a tumor cell in vitro, and thetumor cell can be subsequently administered to a mouse. Vectors can beselected for desirable properties for any particular application.Vectors can be viral or plasmid. Adenoviral vectors are useful in thisregard. Tissue-specific, cell-type specific, or otherwise regulatablepromoters can be used to control the transcription of the inhibitorypolynucleotide molecules. Non-viral carriers such as liposomes ornanospheres can also be used.

Suppression of other major signaling pathways may also be used inconcert with one or more of the inhibitors discussed above. Thesepathways include without limitation, the NFkappa pathway. Additionalmechanisms which may be used in concert include agents to alterepigenetic states, such as histone deacetylase inhibitors and DNAdemethylating agents. Another additional means of inducing thyroidiodide-handling gene expression is to administer thyroid-stimulatinghormone or an analogue such as human recombinant human TSH, Thyrogen™.Any means of inducing the expression of thyroid genes can be used aloneor in concert with others, so that radioiodine treatment can becomeeffective for tumor ablation. Induced expression of may be an increaseof at least 25%, at least 50%, at least 75%, at least 100%, at least2-fold, at least 5-fold, at least 10-fold, at least 20-fold. Maximalinduction in any particular tumor or tumor type of iodide-handling geneexpression is desirable. Any suitable isotope of iodine can be used,including but not limited to ¹²⁵I and ¹³¹I.

Suitable histone deacetylase inhibitors include: hyroxamic acids, suchas Trichostatin A, cyclic tetrapeptides (such as trapoxin B), and thedepsipeptides, benzamides, electrophilic ketones, Panobinostat andaliphatic acid compounds such as phenylbutyrate and valproic acid.Additional inhibitors include SAHA/Vorinostat, Belinostat/PXD101, M275,LAQ824/LBH589, CI994, MGCD0103, nicotinamide, as well derivatives ofNAD, dihydrocoumarin, naphthopyranone, and 2-hydroxynaphaldehydes.Suitable DNA demethylating agents include, without limitation,5-azacytidine (azacitidine) and 5-azadeoxycytidine (decitabine).

Agents for inhibition can be administered to the patient using anyappropriate means known in the art, including oral, intravenous,intramuscular, intrathecal, topical, and subcutaneous administrations.These compositions may be formulated for in vivo administration bydispersion in a pharmacologically acceptable solution or buffer.Suitable pharmacologically acceptable solutions include neutral salinesolutions buffered with phosphate, lactate, Tris, and the like.

Since one aspect of the present invention contemplates the treatment ofcancers with a combination of pharmaceutically active agents that may beadministered separately, the invention further relates to combiningseparate pharmaceutical compositions in kit form. The kit comprises atleast two separate pharmaceutical substances. The kit comprises acontainer for containing the separate compositions such as a dividedbottle or a divided foil packet. Alternately the kit may have at leasttwo of the substances in combination in an undivided container.Additional examples of containers include syringes, boxes and bags.Typically, the kit comprises directions for the use of the components.The kit form is particularly advantageous when the separate componentsare preferably administered in different dosage forms (e.g., oral andparenteral), are administered at different dosage intervals, or whentitration of the individual components of the combination is desired bythe prescribing physician or veterinarian.

The compounds of the present invention can be administered aspharmaceutically acceptable salts, esters, amides or prodrugs. The term“salts” refers to inorganic and organic salts of compounds of thepresent invention. The salts can be prepared in situ during the finalisolation and purification of a compound, or by separately reacting apurified compound in its free base or acid form with a suitable organicor inorganic base or acid and isolating the salt thus formed.Representative salts include the hydrobromide, hydrochloride, sulfate,bisulfate, nitrate, acetate, oxalate, palmitiate, stearate, laurate,borate, benzoate, lactate, phosphate, tosylate, citrate, maleate,fumarate, succinate, tartrate, naphthylate, mesylate, glucoheptonate,lactobionate, and laurylsulphonate salts, and the like. The salts mayinclude cations based on the alkali and alkaline earth metals, such assodium, lithium, potassium, calcium, magnesium, and the like, as well asnon-toxic ammonium, quaternary ammonium, and amine cations including,but not limited to, ammonium, tetramethylammonium, tetraethylammonium,methylamine, dimethylamine, trimethylamine, triethylamine, ethylamine,and the like. See, for example, S. M. Berge, et al., “PharmaceuticalSalts,” J Pharm Sci, 66: 1-19 (1977).

The inhibitors can be administered as prodrugs. The term “prodrug” meanscompounds that are transformed in vivo to yield a compound of thepresent invention. The transformation may occur by various mechanisms,such as through hydrolysis in blood. A discussion of the use of prodrugsis provided by T. Higuchi and W. Stella, “Pro-drugs as Novel DeliverySystems,” Vol. 14 of the A.C.S. Symposium Series, and in BioreversibleCarriers in Drug Design, ed. Edward B. Roche, American PharmaceuticalAssociation and Pergamon Press, 1987.

Recent advances in understanding aberrant signaling of molecularpathways in melanoma provide the bases for the current development ofnovel therapies for this cancer. Of particular importance are the MAPKand PI3K/Akt pathways, which, through their genetic alterations, play acritical role in the development and pathogenesis of melanoma and aretherefore tested vigorously as important therapeutic targets for thiscancer (6,10-15). Several clinical trials targeting these pathways invarious cancers, including melanoma, have been recently completed(9,15,32). Disappointingly, however, little or no anti-tumor responsehas been achieved in these trials, which were single-agent based and,hence, targeted limited pathways. It becomes increasingly questionablewhether targeting only single or limited pathways is an effectivetherapeutic strategy for cancers (15,32). Given the importance of boththe MAPK and PI3K/Akt pathways in melanoma, simultaneously targeting thetwo pathways, instead of either alone, may prove to be a particularlyeffective therapeutic strategy for this cancer. In the present study, wetested this hypothesis by dually and specifically suppressing the MAPkinase and PI3K/Akt pathways in melanoma cells and examining molecularand cellular consequences. Our main theme in this effort was toparticularly test a novel therapeutic strategy of inducing both potentcellular inhibition and thyroid iodide-handling gene expression forpotential adjunct radioiodide therapy for melanoma.

In addition to using specific inhibitors of the pathways, we used shRNAapproaches to simultaneously and specifically knock down Akt-1/2 andBRAF, resulting in synergistic/additive inhibition of melanoma cellproliferation, colony formation and invasion, as well as apoptosis. Dueto the technical complexities and laborious efforts required in shRNAapproaches for simultaneous knockdown of multiple signaling pathways,previous studies on certain cancer cell lines, including one in melanomacells (14), only attempted using drug inhibitors for simultaneoussuppression of the MAPK and PI3K/Akt pathways. The present studyrepresents the first to use the shRNA approach to simultaneously andspecifically knock down the MAPK and PI3K/Akt signaling in cancer cells,definitely demonstrating the therapeutic potential of dually targetingthe two pathways for cancers, such as melanoma. Of particular note inthe present study is that although suppression of either the MAPK orPI3K/Akt pathway could cause significant inhibition of melanoma cellproliferation, suppression of either alone caused little cell apoptosis.Previous studies targeting single pathways using single agents also onlyshowed cell cycle arrest at the G₀/G₁ phase, but not apoptosis, incertain cancer cells (39, 40). These results are consistent with therecent clinical trials on melanoma using single agents that showedlittle anti-tumor effect other than only tumor stability in some cases(9,15,32). Remarkably, the present study showed that combinedsuppression of the MAPK and PI3K/Akt pathways synergistically promotedcell apoptosis, suggesting that both pathways need to be removed toinduce melanoma cell death. This result is consistent with aninteresting previous observation that either pathway was sufficient toprotect melanoma cells from anoikis, a type of apoptosis induced by lossof normal cell contact (41). Thus, therapeutic approaches duallytargeting the MAPK and PI3K/Akt pathways are likely to be more effectivein killing melanoma cells harboring genetic alterations that activateboth pathways. Consequently, it may be expected that a clinical trialusing combined agents targeting both the MAPK and PI3K/Akt pathwayswould likely show significant anti-melanoma effectiveness, unlike therecently completed single agent-based clinical trials (9,15,32).

Radioiodine ablation therapy is an effective and standard treatment forthyroid cancer, which is routinely administered after thyroidectomy inmost thyroid cancer patients (22,23,42,43). This treatment takesadvantage of the unique iodide-handling machinery in thyroid cells,involving several key molecules, such as NIS, TSHR, TPO, Tg, and severalthyroid transcription factors. These genes are frequently silenced inthyroid cancer, particularly in association with aberrant activation ofthe MAPK and PI3K/Akt pathways (18,26-29,44). Suppression of the MAPKand PI3K/Akt pathways could restore the expression of thyroidiodide-handling genes in thyroid cancer cells (39, and Hou and Xing,unpublished data). A previous study interestingly showed that melanomacells also expressed TSHR (33). Based on these data, we suspected thatmelanoma cells might have the ability to express other thyroidiodide-handling genes that were regulated by the MAPK and PI3K/Aktpathways. This was interestingly proven to be the case in the presentstudy. In fact, we demonstrated that suppression of either of the twopathways could induce expression of many of these genes and dualsuppression of the two pathways had a synergistic/additive effect ontheir expression in melanoma cells. As an example, NIS, the mostimportant molecule involved in thyroid cellular uptake of iodide, wasrobustly expressed in the cell membrane with dual suppression of theMAPK and PI3K/Akt pathways either using inhibitors or specific shRNAapproaches. As in normal thyroid cells, TSH significantly enhanced theexpression of these genes induced by suppression of the MAPK andPI3K/Akt pathways in melanoma cells. Importantly, we also demonstratedthat expression of thyroid iodide-handling genes effectively conferredmelanoma cells the ability to take up radioiodide. These results haveimportant novel therapeutic implications for melanoma: radioiodideablation, as in thyroid cancer, might be therapeutically effective formelanoma in conjunction with the use of agents to inhibit the MAPK andPI3K/Akt pathways. For radioiodide treatment of thyroid cancer, TSH isroutinely raised either by thyroxine withdrawal or administration ofhuman recombinant TSH to enhance radioiodide uptake and ablation ofthyroid cancer cells (21,23,42,43). This strategy could be similarlyused for melanoma given the expression of TSHR induced by suppressingthe MAKP and PI3K/Akt pathways and the enhancement of expression ofother iodide-metabolizing genes by TSH in melanoma cells demonstrated inthe present study. In recent years, NIS gene transfer therapy to confernon-thyroid cancers the sensitivity to radioiodide ablation therapy hasbeen widely investigated as a potential therapeutic strategy for humancancers (18,45,46). Yet, the technical complexities, inadequatetherapeutic efficiencies, and other issues associated with NIS genetransfer have so far prevented it from rapid and successful clinicaluse. Our demonstration of the inducibility of thyroid iodide-handlinggenes and radioiodide uptake in melanoma cells opened the possibilityfor a potentially safe, effective, and easy alternative approach totherapeutic use of radioiodide in melanoma. Given the results in thepresent study, it is attractive to propose clinical trials to test thenovel therapeutic strategy of simultaneously targeting the MAPK andPI3K/Akt pathways for both synergistic/additive cellular inhibition andthyroid gene expression for adjunct radioiodide treatment in melanoma.Such clinical tries are feasible particularly given the currentavailability of several safe and potent inhibitors of the MAPK andPI3K/Akt pathways, such as the MEK and Akt inhibitors (9,15,32).

Clinical experience with radioiodine body scan use for thyroid cancerpatients often shows uptake of the radiotracer in the stomach, breast,liver, colon, salivary glands, lacrimal glands and other organs,suggesting the natural expression of some of thyroid-iodide genes inthese organs. We hypothesize that cancers developed in these organs mayalso be induced to robustly express thyroid iodide-handling genes byinhibiting the aberrant signaling pathways in these cancers andtherefore be conferred the ability to avidly take up radioiodine. Wetherefore propose that the novel therapeutic strategy demonstrated herefor melanoma can be applied also to cancers originated in these organsand many other human cancers.

The majority of deaths from thyroid cancer are caused by PDTC and UTC.These cancers, particularly, UTC, are aggressive and usually do notrespond to radioiodine ablation treatment due to the loss of expressionof thyroid iodide-metabolizing genes Gilliland F D, Hunt W C, Morris DM, Key C R. Prognostic factors for thyroid carcinoma. A population-basedstudy of 15,698 cases from the Surveillance, Epidemiology and EndResults (SEER) program 1973-1991. Cancer. 1997; 79:564-573; Cornett W R,Sharma A K, Day T A, et al. Anaplastic thyroid carcinoma: an overview.Curr Oncol Rep. 2007; 9:152-158; Sanders E M Jr, LiVolsi V A, BrierleyJ, Shin J, Randolph G W. An evidence-based review of poorlydifferentiated thyroid cancer. World J Surg. 2007; 31:934-945). There iscurrently no effective medical treatment for radioiodine non-avidthyroid cancers and death or morbidity of patients usually ensues whenthe cancer becomes surgically inoperable. There is an urgent need forthe development of effective treatments for these patients. The recentprogress in understanding the molecular bases, particularly geneticalterations underlying the pathogenesis of aggressive thyroid cancers,provides a unique opportunity to develop novel therapeutic strategies.

In the present study, we proposed that dually targeting the PI3K/Akt andMAP kinase pathways would be therapeutically effective for PDTC and UTC.This hypothesis was based on three molecular bases: 1) Both of the twosignaling pathways have been well documented to play a fundamental rolein tumorigenesis of many human cancers and are potential therapeutictargets in these cancers (Kohno M, Pouyssegur J. Targeting the ERKsignaling pathway in cancer therapy. Ann Med. 2006; 38:200-211; MaroneR, Cmiljanovic V, Giese B, Wymann M P. Targeting phosphoinositide3-kinase-Moving towards therapy. Biochim Biophys Acta. 2007 Oct. 12;[Epub ahead of print]); 2) Activating genetic alterations in the twopathways are extremely common in thyroid cancers, with an increasingprevalence and overlap from differentiated thyroid tumors to PDTC andUTC (1 Garcia-Rostan G, Costa A M, Pereira-Castro I, et al. Mutation ofthe PIK3CA gene in anaplastic thyroid cancer. Cancer Res. 2005;65:10199-1020; Kondo T, Ezzat S, Asa S L. Pathogenetic mechanisms inthyroid follicular-cell neoplasia. Nat Rev Cancer. 2006; 6:292-306; HouP, Liu D, Shan Y, et al. Genetic alterations and their relationship inthe phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. ClinCancer Res. 2007; 13:1161-1170; Costa A M, Herrero A, Fresno M F, et al.BRAF mutation associated with other genetic events identifies a subsetof aggressive papillary thyroid carcinoma. Clin Endocrinol. 2007 Dec. 5;[Epub ahead of print]; Santarpia L, El-Naggar A K, Cote G J, Myers J N,Sherman S I. PI3K/Akt and Ras/Raf-MAPK pathway mutations in anaplasticthyroid cancer. J Clin Endocrinol Metab. 2008; 93:278-284); and 3) We infact have recently demonstrated that genetic alterations that mayaberrantly activate receptor tyrosine kinases and the downstreamPI3K/Akt and MAP kinase pathways occur in virtually all UTC and thosethat can activate both pathways occur in the majority of UTC (Liu Z, HouP, Ji M J, et al. Highly prevalent genetic alterations in receptortyrosine kinases and PI3K/Akt and MAPK pathways in anaplastic thyroidcancers. Cancer Res. 2008). We functionally tested this hypothesis usingNPA and KAT10 cells, which were poorly differentiated orundifferentiated cells derived from thyroid cancer, and both harboredBRAF mutation and PIK3CA amplifications.

The therapeutic potential of targeting the PI3K/Akt pathway has beenpreviously tested in some cancers (Marone R, Cmiljanovic V, Giese B,Wymann M P. Targeting phosphoinositide 3-kinase-Moving towards therapy.Biochim Biophys Acta. 2007 Oct. 12; [Epub ahead of print]). Similarly,previous studies have also tested the therapeutic potential of targetingthe MAP kinase pathway in some cancers (Kohno M, Pouyssegur J. Targetingthe ERK signaling pathway in cancer therapy. Ann Med. 2006; 38:200-211;Sebolt-Leopold J S, Herrera R, Ohren J F. The mitogen-activated proteinkinase pathway for molecular-targeted cancer treatment. Recent ResultsCancer Res. 2007; 172:155-167). Consistent with these previous resultsin other cancers are our data in the present study demonstrating thatsuppression of either of the two pathways could cause significantinhibition of thyroid cancer cell proliferation and invasion, colonyformation, and tumor growth. Our data were also consistent with theresults in some recent in vitro and in vivo studies that targeted at oneof the two signaling pathways with various pharmaceutical agents inthyroid cancer cells (Liu D, Hu S, Hou P, Jiang D, Condouris S, Xing M.Suppression of BRAF/MEK/MAP kinase pathway restores expression ofiodide-metabolizing genes in thyroid cells expressing the V600E BRAFmutant. Clin Cancer Res. 2007a; 13:1341-1349; Liu D, Liu Z, Condouris S,Xing M. BRAF V600E maintains proliferation, transformation, andtumorigenicity of BRAF-mutant papillary thyroid cancer cells. J ClinEndocrinol Metab. 2007b; 92:2264-2271; Ouyang B, Knauf J A, Smith E P,et al. Inhibitors of Raf kinase activity block growth of thyroid cancercells with RET/PTC or BRAF mutations in vitro and in vivo. Clin CancerRes. 2006; 12:1785-1793; Salvatore G, De Falco V, Salerno P, et al. BRAFis a therapeutic target in aggressive thyroid carcinoma. Clin CancerRes. 2006; 12:1623-1629; Liu D, Liu Z, Jiang D, Dackiw A P, Xing M.Inhibitory Effects of the Mitogen-Activated Protein Kinase KinaseInhibitor CI-1040 on the Proliferation and Tumor Growth of ThyroidCancer Cells with BRAF or RAS Mutations. J Clin Endocrinol Metab. 2007c;92:4686-4695; Furuya F, Lu C, Willingham M C, Cheng S Y. (2007).Inhibition of phosphatidylinositol 3-kinase delays tumor progression andblocks metastatic spread in a mouse model of thyroid cancer.Carcinogenesis. 2007; 28:2451-2458).

In the present study, by specific knockdown using shRNA approaches wefor the first time demonstrated the therapeutic potential ofspecifically targeting the PI3K/Akt pathway in thyroid cancer. The moststriking and unique aspect of the present study, however, was thedemonstration that dually targeting PI3K/Akt and MAP kinase pathways wasmore effective and, in many ways, synergistic in inhibiting thyroidcancer cells. This included, for example, the inhibition of thyroidcancer cell proliferation and invasion and, remarkably, the induction ofcell apoptosis and thyroid iodide-metabolizing gene expression. Itshould be emphasized that inhibition of cell proliferation induced bysuppression of a single pathway was mainly through cell cycle arrest atG0/G1 phase whereas dual suppression of the PI3K/Akt and MAP kinasepathways significantly or synergistically increased cell apoptosis. Thisresult suggests that a therapeutic approach dually targeting the twopathways would be far more effective in killing thyroid cancer cells andmay therefore be curative. This may explain some previous studiesshowing that individually targeting the PI3K/Akt or MAP kinase pathwayseemed to only induce slow in vivo growth of thyroid cancer, but notelimination of the tumor, in mice (Liu D, Hu S, Hou P, Jiang D,Condouris S, Xing M. Suppression of BRAF/MEK/MAP kinase pathway restoresexpression of iodide-metabolizing genes in thyroid cells expressing theV600E BRAF mutant. Clin Cancer Res. 2007a; 13:1341-1349; Furuya F, Lu C,Willingham M C, Cheng S Y. (2007). Inhibition of phosphatidylinositol3-kinase delays tumor progression and blocks metastatic spread in amouse model of thyroid cancer. Carcinogenesis. 2007; 28:2451-2458).However, the interpretation of data on tumor in nude mice may needcaution as the immune competency of nude mice may sometimes not becompletely absent. Consequently, survival of human cancer cells in animmunologically unfavorable environment in nude mice could be moresusceptibly affected by knockdown of either of the PI3K/Akt and MAPkinase pathways. This could partially account for the dramaticsuppression of xenograft tumors derived from cells with shRNA knockdownof only one pathway in the present study. Nevertheless, it is convincingbased on the present study that dually targeting the PI3K/Akt and MAPkinase pathways would be significantly more effective and, in fact,necessary in inhibiting, killing, and perhaps curing thyroid cancer inthe human body.

Another unique and exciting finding in the present study was thesynergistic effect of dual knockdown of the PI3K/Akt and MAP kinasepathways, compared with knockdown of either pathway alone, on therestoration of thyroid iodide-metabolizing gene expression. Several suchgenes could be robustly expressed with this approach in contrast withthe limited expression of limited number of thyroid genes in humanthyroid cancer cells demonstrated in previous studies targeting only theMAP kinase pathway (Liu D, Liu Z, Jiang D, Dackiw A P, Xing M.Inhibitory Effects of the Mitogen-Activated Protein Kinase KinaseInhibitor CI-1040 on the Proliferation and Tumor Growth of ThyroidCancer Cells with BRAF or RAS Mutations. J Clin Endocrinol Metab. 2007c;92:4686-4695). As these molecules are classical differentiation markersof thyroid cells, their robust re-expression represents evidence thatdually suppressing the PI3K/Akt and MAP kinase pathways can effectivelypromote re-differentiation of PDTC and UTC cells. More importantly,these results have strong clinical implications with respect toradioiodine ablation treatment for thyroid cancer. It is interesting tonote that in the present study the most responsive gene to induction bysuppressing the PI3K/Akt and MAP kinase pathways was the NIS gene. NISplays a pivotal role in the uptake of iodide by thyroid cells. Therobust expression of NIS gene was demonstrated at both mRNA and proteinlevels, the latter being abundantly transported to the cell membrane asdemonstrated on our flow cytometric and immunoflorescent microscopicanalyses. It is important to note that expression of these genesconferred thyroid cancer cells the functional ability to take upradioiodide. Thus, dual suppression of PI3K/Akt and MAP kinase pathwaysmay restore the radioiodine avidity of PDTC and UTC and confer theresponsiveness of these cancers to radioiodine treatment.

In summary, using specific inhibitors and shRNA knockdown approaches, wetested the therapeutic potential of dually targeting the PI3K/Akt andMAP kinase pathways in PDTC and UTC cells. Although individuallytargeting either pathway alone was previously tested in cancers,including thyroid cancer, the present study was the first to test thesynergistic therapeutic effects of targeting both pathways in humancancers using shRNA approaches. This approach demonstrated remarkableinhibition of poorly differentiated and undifferentiated thyroid cancercells and, more importantly, induction of cell apoptosis and robustthyroid gene expression with restoration of iodide uptake. Given theavailability of several specific, potent and safe inhibitors of thePI3K/Akt and MAP kinase pathways (Kohno M, Pouyssegur J. Targeting theERK signaling pathway in cancer therapy. Ann Med. 2006; 38:200-211;Marone R, Cmiljanovic V, Giese B, Wymann M P. Targeting phosphoinositide3-kinase-Moving towards therapy. Biochim Biophys Acta. 2007 Oct. 12;[Epub ahead of print]; Sebolt-Leopold J S, Herrera R, Ohren J F. Themitogen-activated protein kinase pathway for molecular-targeted cancertreatment. Recent Results Cancer Res. 2007; 172:155-167), duallytargeting the two pathways as a potentially effective therapeuticstrategy for human cancers is clinically possible. This strategy may beparticularly effective for PDTC and UTC in conjunction with radioiodinetherapy conventionally used for thyroid cancer.

The above disclosure generally describes the present invention. Allreferences disclosed herein are expressly incorporated by reference. Amore complete understanding can be obtained by reference to thefollowing specific examples which are provided herein for purposes ofillustration only, and are not intended to limit the scope of theinvention.

EXAMPLES Example 1

Synergistic/Additive Inhibition of Cell Proliferation and Induction ofThyroid Iodide-Handling Gene Expression in Melanoma Cells by DuallySuppressing the MAPK and PI3K/Akt Pathways using Specific Inhibitors.

e first used the melanoma cell line NPA cell, a cell clone derived fromthe melanoma cell line M14 cell (35), and inhibitors of the MAPK andPI3K/Akt pathways to test the therapeutic potential for melanoma ofdully targeting the two pathways to induce potent cell inhibitioncoupled with thyroid iodide-handling gene expression for potentialradioiodide treatment. As shown in FIG. 1A, treatment of cells with theMEK inhibitor U0126 and the Akt inhibitor IV (Akti IV) (.38) stronglyinhibited phosphorylation of ERK (p-ERK) and Akt (p-Akt), respectively.Correspondingly, the two inhibitors inhibited cell proliferationpartially when used individually and virtually completely when used incombination (FIG. 1B). To explore the ability of suppressing the MAPKand PI3K/Akt pathways to induce the expression of iodide-metabolizinggenes in melanoma cells, we tested the effects of U0126 and Akti IV onNPA cells which had no or low basal expression of iodide-handling genes.As shown in FIG. 1C, expression of several iodide-handling genes,including NIS, TSHR, Tg, and TTF1, was induced or dramatically enhancedafter treatment of cells with U0126 or Akti IV. Combined use of the twoinhibitors showed synergistic/additive effects in promoting theexpression of some of these genes (FIG. 1C). Similar effects of theseinhibitors of the MAPK and PI3K/Akt pathways on cell inhibition andiodide-handling gene expression were seen in DRO cells, a cell clonederived from the melanoma cell line A375 cell (35) (data not shown).

Example 2

Expression of Iodide-Handling Genes in Various Melanoma Cell LinesInduced by Suppressing the MAPK and PI3K/Akt Pathways and itsEnhancement or Synergy by TSH Stimulation.

Encouraged by the novel finding of the expression of iodide-handlinggenes upon suppression of the MAPK and PI3K/Akt pathways in the NPAcell, we extended this study to other melanoma cell lines. As shown inFIG. 2, in several melanoma cell lines tested, including M14, UACC62,A-375 and, again, NPA cells, dually suppressing the MAPK and PI3K/Aktpathways by U0126 and Akti IV showed synergistic/additive effects on theexpression of most of the iodide-handling genes compared withsuppressing either pathway alone. Since TSHR plays an important role inup-regulating the iodide-handling genes in thyroid cells (21) and isexpressed in melanoma cells upon suppression of the MAPK and PI3K/Aktpathways, we investigated whether TSH treatment could affect theexpression of iodide-handling genes in melanoma cells. Remarkably,treatment of melanoma cells with TSH enhanced or synergized theexpression of many of the iodide-handling genes induced either bysuppression of one signaling pathway alone or simultaneous suppressionof both pathways (FIG. 2A-2B).

Example 3

Cellular Inhibition of Melanoma Cells by siRNA Knockdown of BRAF andAkt-1/2.

The above findings from the experiments using pharmacological inhibitorsstrongly suggest that dually targeting the MAPK and PI3K/Akt signalingpathways to induce both cellular inhibition and thyroid gene expressionfor adjunct radioiodine ablation therapy could be a novel and effectivetherapeutic strategy for melanoma. To more specifically test thishypothesis, in the next series of experiments, we used siRNA approachesto specifically knock down the MAPK and PI3K/Akt pathways, individuallyor dually in a selected melanoma cell line, the NPA cell. We pursuedstable transfection with dual knockdown of Akt-1 and Akt-2 incombination with BRAF knockdown to achieve dual suppression of the twosignaling pathways. To this end, we stably transfected NPA cells withpSicoR-PGK-euro encoding specific shRNA homologue sequences for Akt-1and Akt-2 (Akt-1/2), superimposed with or without stable transfection ofspecific BRAF siRNA. Cells stably infected with lentivirus expressingBRAF and Akt-1/2 siRNA were successfully selected using puromycin, asdemonstrated by effective suppression of expression of the correspondingproteins. Specifically, as shown in FIG. 3A, BRAF and Akt-1/2 siRNAstably and virtually completely inhibited the expression of BRAF andAkt-1/2, respectively, compared with empty vectors. As shown in FIG. 3Band C, specific BRAF siRNA strongly inhibited proliferation andtransformation of cells. Similarly, specific Akt-1/2 siRNA alsoexhibited dramatic inhibition of cell proliferation and transformation(FIGS. 3B and 3C). Further inhibition of cell proliferation andtransformation was achieved by dual knockdown of BRAF and Akt-1/2 (FIGS.3B and 3C). Migration/invasion of the NPA cells on Matrigel was alsoinhibited by stable siRNA knockdown of either pathway, with furtherinhibition achieved with dual knockdown of the two pathways (FIG. 4).

Example 4

Induction of G₀/G₁ Cell Cycle Arrest and Apoptosis by siRNA Knockdown ofBRAF and Akt-1/2.

To investigate further the cellular events involved in the inhibition ofcell proliferation by dual suppression of MAPK and PI3K/Akt pathways, wetransiently transfected BRAF and Akt-1/2 siRNA in NPA cells and measuredcell cycle and apoptotic patterns by flow cytometric analysis of DNAcontent and Annexin V expression (FIG. 5). Compared with control vector,siRNA knockdown of BRAF and Akt-1/2 caused an increase in the G₀/G₁fraction from 65.9% to 81.5% (by 23.7%) and to 74.2% (by 12.6%),respectively (FIG. 5A). With dual knockdown of BRAF and Akt-1/2, therewas a dramatic synergistic increase in the sub-Go fraction in comparisonwith control vector or knockdown of BRAF or Akt-1/2 alone (9.5% vs.0.4-1.4%), reflecting increased cell apoptosis, and the G₀/G₁ fractionwas correspondingly only moderately increased. These data wereconsistent with the apoptotic patterns shown in FIG. 5B, which showed adramatic increase in both early and late apoptosis (9.7% and 13.4%,respectively) with dual knockdown of BRAF and Akt-1/2. In contrast,knockdown of BRAF or Akt-1/2 alone had a much smaller effect on cellapoptosis. These data suggest that both increased G₀/G₁ cell cyclearrest and cell apoptosis were involved in the inhibition of NPA cellgrowth by suppression of MAPK and PI3K/Akt pathways. The effects weremost significant with dual knockdown of the MAPK and PI3K/Akt pathways,particularly for cell apoptosis.

Example 5

NIS Protein Expression and Radioiodide Uptake in Melanoma Cells Inducedby Suppressing the MAPK and PI3K/Akt Pathways.

As NIS plays the most important role in cellular iodide uptake, we nextexplored further the effect of suppressing the MAPK and PI3K/Aktpathways on NIS expression in melanoma cells. As shown in FIG. 6A,stable knockdown of BRAF and/or Akt-1/2 with specific siRNA induced theexpression of NIS in NPA cells, consistent with the results achievedwith treatments of cells with pharmacological inhibitors (FIG. 1C andFIG. 2A-2B). We next investigated the effects of suppressing the MAPKand PI3K/Akt pathways on the expression of NIS protein in NPA cells. Asshown in FIG. 6B, U0126 and Akti IV increased the NIS expression from3.4% to 6% and 13.7%, respectively, and to 19% with combination of thetwo (FIG. 6B, upper panel). Although both U0126 and Akti IV induced NISprotein expression, Akti IV showed a more pronounced effect (FIG. 6B,upper panel). Combination of U0126 and Akti IV showed significantlyenhanced or synergized effects on NIS protein expression (FIG. 6B, upperpanel). Similarly, siRNA knockdown of BRAF and Akt-1/2 could eachincrease the NIS protein expression, albeit modestly, and dual knockdownof BRAF and Akt-1/2 showed enhanced effects (FIG. 6B, lower panel). Wealso performed immunofluorescent microscopy, which showed that dualinhibition of the MAPK and PI3K/Akt pathways by U0126 and Akti IVrobustly induced the expression of NIS protein on cell membranes (FIG.6C).

Given the induction of expression of iodide-handling genes in melanomacells by suppression of the MAPK and PI3K/Akt pathways, we finallyexamined functionally the ability of these cells to take up radioiodide.As shown in FIG. 6D, treatment of NPA cells with U0126 or Akti IVsignificantly increased radioiodide uptake and combination of the twoinhibitors resulted in an enhanced uptake. Stable knockdown of BRAF orAkt-1/2 could also increase radioiodide uptake, which was enhanced bysimultaneous knockdown of the two.

Example 6 for Ex. 1-5

Materials and Methods

Human melanoma cell lines and cell culture The melanoma cell line UACC62was obtained from the National Cancer Institute (NCI); melanoma cellslines M14 and A375 were obtained from American Type Culture Collection(ATCC). The NPA cell was provided by Dr. Guy J. F. Juillard (Universityof California-Los Angeles School of Medicine, Los Angeles, Calif.). Thiscell was previously mistakenly labeled as a thyroid cancer cell line(34) and has now been demonstrated to be a clone derived from themelanoma cell line M14 (35). NPA, M14 and UACC62 cells harbor geneticalterations that can activate both the MAPK and PI3K/Akt pathways: BRAFV600E mutation and PIK3CA amplifications in NPA and M14 cells, and BRAFV600E mutation and inactivating PTEN mutations (homozygous) in UACC62cells. A375 harbors BRAF V600E mutation. Cells were cultured similarlyas previously described (34,36). In some experiments as indicated, cellswere additionally treated with bovine TSH (TSHI3) (Sigma) to test itseffect on gene expression.

Western blotting assay. Cells were lysed in RIPA buffer. Cellularproteins were resolved by electrophoresis on a SDS-polyacrylamide (10%)gel (SDS-PAGE), transferred onto PVDF membranes (Amersham PharmaciaBiotech, Piscataway, N.J.), and immunoblotted with specific primaryantibodies. Anti-BRAF (Sc-166), anti-phospho-AKT (Sc-7985-R),anti-phospho-ERK (Sc-7383), and anti-Actin (Sc-1616-R) were purchasedfrom Santa Cruz (Santa Cruz, Calif.). Anti-Akt-1 (#2967) and anti-Akt-2(#2964) were purchased from Cell Signaling Technologies, Inc. (Beverly,Mass.). Antigen-antibody complexes were visualized using HRP-conjugatedanti-mouse (Sc-2005, Santa Cruz, Calif.) or anti-rabbit (Sc-2004, SantaCruz, Calif.) IgG antibodies and ECL Western Blotting Analysis System(Amersham Pharmacia).

RNA extraction, RT-PCR analysis, and quantitative RT-PCR analysis. TotalRNA was isolated using TRIzol reagent according to the instructions ofthe manufacturer (Invitrogen). Normal human thyroid RNA samplespurchased from Stratagene (La Jolla, Calif.) were used as a positivecontrol. The reverse transcription synthesis of cDNA was conducted withthe SuperScript First-Strand Synthesis kit (Invitrogen). ConventionalRT-PCR amplification was carried out to amplify NIS, TSHR, Tg, TPO,PAX8, FOXE1, and TTF1. The β-actin gene was run in parallel for qualitycontrol. The primer sequences were presented in Table 1. PCR productswere resolved by 1.5% agarose gel electrophoresis and visualized byethidium bromide staining. Quantitative RT-PCR analysis was performed toevaluate expression of thyroid genes on an ABI Prism 7900HT SequenceDetector (Applied Biosystems), using SYBR Green PCR Core Reagents kitaccording to the instructions of the manufacturer (Applied Biosystems).The expression value of each gene was normalized to β-actin cDNA tocalculate the relative amount of RNA present in each sample. The primersof intron-spanning thyroid-specific genes, NIS, TSHR, Tg, TPO, PAX8,FOXE1, and TTF1 were designed using Primer Express (Applied Biosystems,CA) and presented in Table 2.

TABLE 1 Hairpin RNA sequences used to specifically knock down BRAF, Akt-1 and -2 Forward sequence Reverse sequence Genes (5′→3′)(5′→3′) BRAF TGCATCAATGGATACCGTTAT TCGAGAAAAAAGCATCAATGGATATCAAGAGATAACGGTATCCAT CCGTTATCTCTTGAATAACGGTAT TGATGCTTTTTTC CCATTGATGCA(SEQ ID NO: 5) (SEQ ID NO: 7) Akt- TGTGGTCATGTACGAGATGATTCGAGAAAAAAGTGGTCATGTACG 1/2 TCAAGAGATCATCTCGTACATAGATGATCTCTTGAATCATCTCGT GACCACTTTTTTC ACATGACCACA (SEQ ID NO: 6)(SEQ ID NO: 8)

TABLE 2 Primer sequences used in RT-PCR analysis of the expression of thyroid iodide-handling genes Pro- Forward primerReverse primer duct Genes (5′→3′) (5′→3′) length NISCTATGGCCTCAAGTTCCTCT TCGTGGCTACAATGTACTGC 179 bp (SEQ ID NO: 9)(SEQ ID NO: 17) TSHR ATCAGGAGGAGGACTTCAGA TTTGAGGGCATCAGGGTCTA 274 bp(SEQ ID NO: 10) (SEQ ID NO: 18) Tg GCAAAGGCTGTGAAGCAATTTGATAAAGTAGTCCCGGGTG 211 bp (SEQ ID NO: 11) (SEQ ID NO: 19) TPOCATTGGGAAGCAGATGAAGG TGTTGTCACAGATGACCCGA 128 bp (SEQ ID NO: 12)(SEQ ID NO: 20) PAX8 CAGGCATGGTGGCAGGAAGT ACAGATGGTCAAAGGCCGTG 177 bp(SEQ ID NO: 13) (SEQ ID NO: 21) FOXE1 GCTGGTTTTCCCTGTCTCTGAGATGGGGGAGACTGAAGGT 100 bp (SEQ ID NO: 14) (SEQ ID NO: 22) TTF1TACTGCAACGGCAACCTGGG GGCCATGTTCTTGCTCACGT 207 bp (SEQ ID NO: 15)(SEQ ID NO: 23) β- TCTACAATGAGCTGCGTGTG TAGATGGGCACAGTGTGGGT 228 bpActin (SEQ ID NO: 16) (SEQ ID NO: 24)

Lentivirus-mediated RNA interference of BRAF, Akt-1, and Akt-2. Thelentiviral pSicoR-PGK-puro vectors (Addgene Inc. Cambridge, Mass., USA)encoding hairpin RNA sequences were used to knock-down BRAF and specificAkt isoforms. The hairpin sequences used for BRAF and combined Akt-1 andAkt-2 (Akt-1/2) were presented in Table 3. To generate lentiviralparticles, human embryonic kidey 293 cells (ATCC, Manassas, Va., USA)were co-transfected with the lentiviral vector and compatible packagingplasmid mixture using Lipofectamine 2000 (Invitrogen), following themanufacturer's instructions. Melanoma cells were exposed tolentivirus-containing supernatant for 16 hours in the presence ofPolybrene (Sigma). After 3-4 days, the cells were serum-starved (0.5%FBS) and harvested 24 hours later in RIPA lysis buffer (Santa Cruz,Calif.). Western blotting assays were used to detect the proteinexpression of BRAF, Akt-1, and Akt-2.

TABLE 3 Primer sequences used for quantitative RT-PCRanalysis of the expression of thyroid iodide- handling genes Pro-Forward primer Reverse primer duct Genes (5′→3′) (5′→3′) length NISCCTGCTAACGACTCCAGCA CCAGGGCACCGTAATAGAGA 106 bp (SEQ ID NO: 25)(SEQ ID NO: 33) TSHR GATATTCAACGCATCCCCAG AGCTGCTGCAGAGTCACATC 149 bp(SEQ ID NO: 26) (SEQ ID NO: 34) Tg CACCAACTCCCAACTTTTCCCAACTGACCTCCTTTGCCA 123 bp (SEQ ID NO: 27) (SEQ ID NO: 35) TPOACTTGGATCTCCATGTCGCT GCAGTGTGGATTTAGTGCCA 106 bp (SEQ ID NO: 28)(SEQ ID NO: 36) PAX8 TGCCTCACAACTCCATCAGA CAGGTCTACGATGCGCTG 110 bp(SEQ ID NO: 29) (SEQ ID NO: 37) FOXE1 GCTGGTTTTCCCTGTCTCTGAGATGGGGGAGACTGAAGGT 100 bp (SEQ ID NO: 30) (SEQ ID NO: 38) TTF1ACCAGGACACCATGAGGAAC GCTCATGTTCATGCCGCT  116 bp (SEQ ID NO: 31)(SEQ ID NO: 39) β- GCACAGAGCCTCGCCTT GTTGTCGACGACGAGCG  93 bp Actin(SEQ ID NO: 32) (SEQ ID NO: 40)

Cell proliferation assay. Cells (800/well) were seeded into 96-wellplates and cultured with 2.5% FBS. MTT assay was performed daily over a5-day time course to evaluate cell numbers using a MTT cellproliferation assay kit (ATCC, Manassas, Va., USA) following themanufacturer's instructions.

Colony formation assay. For soft-agar colony-formation assay, 1×10⁵cells were plated into 6-well plates with a bottom layer of 0.6% agarand a top layer of 0.3% agar. Following the hardening of soft agar,plates were incubated at 37° C. with 5% CO₂. After 2-3 weeks of culture,colonies were counted and photographed under a microscope.

Cell invasion assay. Cell invasion was assayed in triplicates usingMatrigel-coated Transwell cell culture chambers (#354481, BDBiosciences). Briefly, cells (1.5×10⁵ cells/well) suspended inserum-free medium were placed in the upper chamber of the Transwellinsert, and RPMI 1640 medium containing 10% FBS was added to the lowerchamber. Following a 24h-incubation at 37° C. with 5% CO2, non-invasivecells in the upper chamber were removed and invasive cells were fixed in100% methanol and stained with 0.5% crystal violet in 2% ethanol. Thenumbers of invasive cells were counted and photographed.

Cell cycle analysis. Cells were harvested, washed twice in PBS, andresuspended in 70% ethanol on ice for at least 30 min. Aftercentrifugation, 1×10⁶ cells transiently transected with various siRNAconstructs were resuspended in 1 ml of propidium iodide stainingsolution (50 μg of propidium iodide, 1 mg of RNase A, and 1 mg ofglucose per 1 ml PBS) and incubated at room temperature for 30 min. Cellcycles were analyzed based on DNA contents by FACS using a LSR FlowCytometer (BD Biosciences, N.J.).

Apoptosis assay. Cells were transiently transfected with various siRNAconstructs. After a 24-h serum starvation, cells were harvested, washedwith PBS, and subjected to sequential staining with Annexin V-PEApoptosis Detection Kit (BD Biosciences) by two-color flow cytometry,according to the manufacturer's protocol. Cells that were AnnexinV-positive and 7-AAD-negative served as early apoptotic population.Cells that were both Annexin V- and 7-AAD-positive served as lateapoptotic population.

Flow cytometry analysis of NIS expression. Cells treated with specificinhibitors and various siRNA constructs to induce the expression of NISwere incubated with VJ2 α-hNIS mAb (a gift from Dr. Sabine Costagliolaat the Free University of Brussels) (37) diluted at 1:20 in FACS buffer(3% FBS, 0.02% NaN₃ in PBS) at 4° C. for 1 h. Cells were then washedonce with FACS buffer and incubated with FITC-conjugated a-mouse IgG(Sigma) diluted at 1:100 in FACS buffer at 4° C. for 1 h. Cells werewashed again in FACS buffer, resuspended in 2 ml of FACS buffer with7-AAD, and analyzed by FACS using a LSR Flow Cytometer (BD Biosciences,N.J.). Secondary antibody alone was used as a negative control.Fluorescent microscopic examination was conducted to monitor NISexpression (Nikon Corporation, Tokyo, Japan).

Radioactive iodine uptake assay. Cells (1×10⁶ cells/well) treated underthe indicated conditions were seeded in 12-well plates. Cells in 0.5ml/well were incubated with RPMI 1640 medium containing 1 μCi Na¹²⁵I and5 μM non-radioactive NaI for 1 h at 37° C. with 5% CO₂. The medium wassubsequently aspirated and cells were quickly washed twice with ice-coldHank's balanced salt solution (HBSS) and harvested with tripsin-EDTA.Cells were collected and radioactivity was counted by a gamma-counter.

Statistical analysis. All the experiments were similarly done at leastthree times. The statistical significance of differences between twogroups of data was analyzed by paried t-test and a P value of <0.05 wasconsidered significant.

Example 7

Inhibition of Cell Proliferation and Restoration of Iodide-MetabolizingGene Expression in Thyroid Cancer Cells by Dually Suppressing thePI3K/Akt and MAP Kinase Pathways Using Specific Inhibitors

As the first step to explore the therapeutic potential of dullytargeting the PI3K/Akt and MAP kinase pathways, we tested the effects ofspecific inhibitors of the two pathways in thyroid cancer cell lines NPAand KAT10 cells, which were poorly differentiated or undifferentiatedand harbored activating genetic alterations in both PI3K/Akt and MAPkinase pathways. As shown in FIG. 7A, the Akt inhibitor IV (Akti IV) andthe MEK inhibitor U0126 strongly inhibited phosphorylation of Akt(p-Akt) and ERK (p-ERK), respectively, in both cells. Correspondingly,the two inhibitors inhibited cell proliferation partially when usedindividually and virtually completely when used in combination in bothcells (FIG. 7B). To explore the role of PI3K/Akt and MAP kinase pathwaysin the expression of thyroid iodide-metabolizing genes, we tested theeffects of Akti IV and U0126 on NPA and KAT10 cells which virtually hadno or very low basal expression of most of the iodide-metabolizinggenes. As shown in FIG. 7C, expression of several thyroid genes,including Tg, TSHR, NIS, and TTFJ, was restored after treatment of thecells with Akti IV or U0126. Remarkably, combined use of the twoinhibitors showed a dramatic synergistic effect in promoting there-expression of these genes, particularly Tg, TSHR, and NIS (FIG. 7C).Similar effects of these inhibitors of the PI3K/Akt and MAP kinasepathways on cell inhibition and thyroid gene re-expression were seen inKAKI, KAT5, KAT7, ARO and C643 thyroid cancer cell lines (data notshown). TPO and PAX8 genes were naturally robustly expressed in thesecells (data not shown) and were therefore not investigated in thepresent study.

Example 8

Inhibition of Cell Proliferation and Transformation by siRNA knockdownof Akt-1, Akt-2, and BRAF

Given these encouraging data on pharmacological inhibitors in thyroidcancer cells, we took the next steps to specifically explore thetherapeutic potential of interfering with PI3K/Akt and MAP kinasepathways in thyroid cancer using specific siRNA approaches. Among theseveral isoforms of Akt, Akt-1 and Akt-2 were shown to be particularlyabundant and important in thyroid cancer (Ringel M D, Hayre N, Saito J,et al. Overexpression and overactivation of Akt in thyroid carcinoma.Cancer Res. 2001; 61:6105-6111). We therefore first examined theindividual role of Akt-1 or Akt-2 using transient siRNA transfection toindividually knock down the two Akts. To this end, we used KAT10 cellsto perform siRNA transfection using the lentiviral vector pSicoR-PGK-GFPthat encoded short hairpin RNA (shRNA) sequences to specificallydown-regulate the expression of Akt-1 or Akt-2. To dually interfere withthe PI3K/Akt and MAP kinase pathways, KAT10 cell clones stablytransfected with BRAF-specific siRNA (clone C9) or control scrambledsiRNA (clone 2B2) that had been previously established (Liu D, Hu S, HouP, Jiang D, Condouris S, Xing M. Suppression of BRAF/MEK/MAP kinasepathway restores expression of iodide-metabolizing genes in thyroidcells expressing the V600E BRAF mutant. Clin Cancer Res. 2007a;13:1341-1349; Liu D, Liu Z, Condouris S, Xing M. BRAF V600E maintainsproliferation, transformation, and tumorigenicity of BRAF-mutantpapillary thyroid cancer cells. J Clin Endocrinol Metab. 2007b;92:2264-2271) were used for superimposed transfection with Akt-1 orAkt-2 siRNA. As shown in FIG. 8A, specific Akt-1, Akt-2 and BRAF siRNAvirtually completely suppressed the expression of their correspondingproteins. This high efficiency of transfection with the pSicoR-PGK-GFPvector was also confirmed by the persistent expression of the tag GFPeven at 2 weeks on fluorescent microscopy (FIG. 8B). Knockdown of eitherAkt-1 or Akt-2 had a significant inhibitory effect on thyroid cancercell proliferation (FIG. 8C) and colony formation on soft agar(representing cell transformation) (FIG. 8D). Compared with BRAF controlsiRNA (2B2/V), knockdown of BRAF (C9/V) also had a significantinhibitory effect on cell proliferation and colony formation (FIGS. 8Cand 8D) as demonstrated previously (Liu, supra). Combinational knockdownof Akt-1 or Akt-2 with BRAF caused a further inhibition of thyroidcancer cell proliferation and colony formation (FIGS. 8C and 8D).

These data suggested that Akt-1 and Akt-2 individually played asignificant but partial role in thyroid cancer cell growth. Based onthese data from transient siRNA transfection, we next pursued stabletransfection with dual knockdown of Akt-1 and Akt-2 in combination withBRAF knockdown to achieve maximal dual suppression of PI3K/Akt and MAPkinase signalings. To this end, we stably transfected NPA and KAT10cells with pSicoR-PGK-puro encoding specific shRNA homologue sequencesfor Akt-1 and Akt-2 (Akt-1/2), superimposed with or without stabletransfection of specific BRAF siRNA. Thyroid cancer cells stablyinfected with lentivirus expressing Akt-1/2 and BRAF siRNA weresuccessfully selected using puromycin, as demonstrated by effectivesuppression of expression of the corresponding proteins. Specifically,as shown in FIG. 9A, Akt-1/2 and BRAF siRNA stably and virtuallycompletely inhibited the expression of Akt-1/2 and BRAF, respectively,in both NPA and KAT10 cells compared with empty vectors. As seen withthe pSicoR-PGK-GFP system (FIG. 8), stable BRAF siRNA transfection withthe pSicoR-PGK-puro system strongly inhibited cell proliferation andtransformation of both NPA and KAT10 cells (FIGS. 9B and 9C). Similarly,specific Akt-1/2 siRNA also exhibited dramatic inhibition of thyroidcancer cell proliferation and transformation (FIGS. 9B and 9C).Significant further inhibition of cell proliferation and transformationwas achieved by dual knockdown of Akt-1/2 and BRAF (FIGS. 9B and 9C).These stable transfectants were used in most of the followingexperiments to further explore the therapeutic potential of duallytargeting both PI3K/Akt and MAP kinase pathways in thyroid cancer cells.

Example 9

Inhibition of Cell Invasion by Stable siRNA Knockdown of Akt-1/2 andBRAF

To investigate whether suppression of PI3K/Akt and MAP kinase pathwayscould suppress invasion of thyroid cancer cells, we performed Matrigelinvasion assay on NPA and KAT10 cells stably expressing Akt-1/2 and BRAFsiRNA. As shown in FIG. 10, the number of invading cells was stronglyinhibited with knockdown of Akt-1/2 or BRAF compared with empty vector.Dual siRNA knockdown of Akt-1/2 and BRAF caused further inhibition ofcell invasion, particularly in NPA cells (FIG. 10).

Example 10

Promotion of G₀/G₁ Cell Cycle Arrest and Apoptosis by siRNA knockdown ofAkt-1/2 and BRAF

To investigate further the cellular events involved in the inhibition ofcell proliferation by dual suppression of PI3K/Akt and MAP kinasepathways, we transiently transfected Akt-1/2 and BRAF siRNA in NPA andKAT10 cells and measured cell cycle and apoptotic patterns by flowcytometric analysis of DNA content and Annexin V staining (FIG. 11). InNPA cells, compared with control vector, siRNA knockdown of Akt-1/2 andBRAF caused an increase in the G₀/G₁ fraction from 65.9% to 74.2% (by12.6%) and to 81.5% (by 23.7%), respectively (FIG. 11A, upper panel).With dual knockdown of Akt-1/2 and BRAF, there was a dramaticsynergistic increase in the sub-Go fraction in comparison with controlvector or knockdown of Akt-1/2 or BRAF alone (9.5% vs. 0.4-1.4%),reflecting increased cell apoptosis, and the G₀/G₁ fraction wascorrespondingly only moderately increased. These data were consistentwith the apoptotic patterns shown in FIG. 11A, lower panel, which showeda dramatic increase in both early and late apoptosis (9.7% and 13.4%,respectively) with dual knockdown of Akt-1/2 and BRAF. In contrast,knockdown of Akt-1/2 or BRAF alone had a much smaller effect on cellapoptosis. In KAT10 cells, siRNA knockdown of Akt-1/2 and BRAF increasedthe G₀/G₁ fraction from 72% to 79% (by 10%) and 85% (by 18%),respectively, and to 90% (by 25%) with dual knockdown of Akt-1/2 andBRAF (FIG. 11B, upper panel). An increase, albeit modest, in lateapoptosis was also seen with individual or dual knockdown of Akt-1/2 andBRAF in KAT-10 cells (FIG. 11B, lower panel). These data suggest thatboth increased G₀/G₁ cell cycle arrest and cell apoptosis were involvedin the inhibition of NPA and KAT-10 cell growth by suppression ofPI3K/Akt and MAP kinase pathways, which were most pronounced with dualknockdown of the PI3K/Akt and MAP kinase pathways.

Example 11

Inhibition of Tumorigenicity and In Vivo Tumor Growth of Thyroid CancerCells by Stable siRNA Knockdown of Akt-1/2 and BRAF

To more directly assess the therapeutic potential of targeting PI3K/Aktand MAP kinase pathways for thyroid cancer, we tested the effects ofknockdown of these pathways on tumor formation and growth from KAT-10cells in nude mice. As shown in FIG. 12, emerging tumors became visiblein most mice within 0.5 wk after inoculation of cells. Although thetumor volume progressively grew in all groups, a much slower pace wasseen with siRNA knockdown of Akt-1/2 and BRAF and dual knockdown of thetwo (FIG. 12A). After two weeks, tumors started shrinking in all thesiRNA knockdown groups while tumors in the control group continued togrow. As knockdown of Akt-1/2 and BRAF each alone already caused aremarkable inhibition of tumor growth, dual knockdown of the two onlyslightly further decreased the tumor size (FIGS. 12B and 12C). Sometumors in the siRNA knockdown groups virtually disappeared at 3.5 wk. Atthis time, the average weight of the tumors in the 4 groups (each withn=5) were 0.99±0.16 g for the control, 0.03±0.03 g for Akt-1/2 siRNAknockdown, 0.03±0.03 g for BRAF siRNA knockdown, and 0.014±0.02 g fordual knockdown, respectively (mean±SD; P<0.01). FIG. 12B shows the tumorweight of each individual mouse in all groups, more clearly illustratingthe inhibition of the tumor by specific Akt-1/2 and BRAF knockdownindividually or in combination. FIG. 12C shows representative tumorsfrom the control and the three siRNA knockdown groups before and aftersurgical removal.

Example 12

Restoration of Iodide-Metabolizing Gene Expression by Stable siRNAKnockdown of Akt-1/2 and BRAF

We next assessed the restorability of thyroid gene expression bysuppression of the PI3K/Akt and MAP kinase pathways in NPA and KAT-10cells with stable siRNA knockdown of Akt-1/2 and BRAF. As shown in FIG.13A, expression of NIS, TSHR, and TTF 1 could be restored by siRNAknockdown of BRAF and only expression of NIS could be restored byAkt-1/2 knockdown. Remarkably, dual knockdown of Akt-1/2 and BRAF had adramatic synergistic effect on the expression of these genes (FIG. 13A).In KAT-10 cells, Akt-1/2 and BRAF knockdown individually could onlyrestore the expression of NIS (FIG. 13B). Their dual knockdownsynergized the expression of NIS. Expression of Tg and TSHR could beslightly restored by dual siRNA knockdown of Akt-1/2 and BRAF (FIG.13B). RT-PCR confirmed the expression of NIS (FIG. 13C), which wasconsistent with the results of quantitative real-time PCR (FIGS. 13A andB).

Example 13

Restoration of NIS Protein Expression and the Ability to Take UpRadioiodine in Thyroid Cancer Cells by Suppression of PI3K/Akt and MAPkinase Pathways

To specifically investigate the effect of suppression of PI3K/Akt andMAP kinase pathways on the expression of NIS protein, NPA and KAT10cells were treated with specific inhibitors (Akti IV for Akt, and U0126for MEK) or stably transfected with various siRNA constructs. In NPAcells, Akti IV and U0126 increased the NIS expression from 3.4% to 13.7%and 6%, respectively, and to 19% with combination of the two (FIG. 14A,upper panel). In KAT10 cells, Akti IV and U0126 increased the NISexpression from 8.8% to 29% and 11.8%, respectively, and to 41% withcombination of the two (FIG. 14A, upper panel). Although both Akti IVand U0126 induced NIS protein expression, Akti IV showed a morepronounced effect in both NPA and KAT10 cells (FIG. 14A, upper panel).Consistent with the quantitative real-time PCR results on mRNAexpression (FIG. 14C), combination of Akti IV and U0126 showedsignificantly enhanced or synergized effects on NIS protein expression(FIG. 14A, upper panel). Similarly, siRNA knockdown of Akt-1/2 and BRAFcould each increase the NIS protein expression, albeit modestly, anddual knockdown of Akt-1/2 and BRAF showed enhanced effects in both NPAand KAT10 cells (FIG. 14A, lower panel). We also performedimmunofluorescent microscopy, which showed that dual inhibition ofPI3K/Akt and MAP kinase pathways by Akti IV and U0126 robustly restoredthe expression of NIS protein on the membranes of NPA and KAT10 cells(FIG. 14B).

Given the restoration of expression of thyroid iodide-metabolizing genesin NPA and KAT10 cells by suppression of PI3K/Akt and MAP kinasepathways, we examined functionally the ability of these cells to take upradioiodide. As shown in FIG. 14C, treatment of NPA and KAT10 cells withU0126 or Akti IV significantly increased Na¹²⁵I uptake and combinationof the two inhibitors showed an enhanced effect. Stable knockdown ofAkt-1/2 or BRAF could also increase radioiodide uptake, which wasenhanced with dual knockdown of the two, albeit less robustly comparedwith drug treatments. Compared with KAT10 cells, radioiodine uptake wasmore pronounced in NPA cells (FIG. 14C), consistent with the pattern ofNIS protein expression that was also more pronounced in living NPA cells(FIG. 14A).

Example 14

Materials and Methods for Examples 7-13

Cell Culture

Human thyroid cancer NPA and KAT10 cells, which were poorlydifferentiated or undifferentiated cancer cell lines (Fagin J A, MatsuoK, Karmakar A, Chen D L, Tang S H, Koeffler H P. High prevalence ofmutations of the p53 gene in poorly differentiated human thyroidcarcinomas. J Clin Invest. 1993; 91:179-184; van Staveren W C, Solis DW, Delys L, et al. Human thyroid tumor cell lines derived from differenttumor types present a common dedifferentiated phenotype. Cancer Res.2007; 67:8113-8120), were from Dr. Guy J. F. Juillard (University ofCalifornia-Los Angeles School of Medicine, Los Angeles, Calif.) and Dr.Kenneth B. Ain (University of Kentucky Medical Center, Lexington, Ky.),respectively. Both of the two thyroid cancer cells lines harbor geneticalterations that could activate both PI3K/Akt and MAP kinase pathways:BRAF V600E (homozygous) and PIK3CA amplification for NPA cells and BRAFV600E (heterozygous) and PIK3CA amplification for KAT10 cells. Celllines were routinely grown at 37° C. in RPMI 1640 medium with 10% fetalbovine serum (FBS) and 5% carbon dioxide. For NPA cells, 77 mg sodiumpyruvate (Irvine Scientific, Santa Ana, Calif.), 750 mg sodiumbicarbonate (Invitrogen), 7 mL of 100× MEM nonessential amino acid(Irvine Scientific), 5 mL of 100× antimycotic solution (OmegaScientific, Tarzana, Calif.), and 1 mL of 50 mg/mL gentamicin(Invitrogen), in each 500 mL medium, were also supplemented. In someexperiments, to block the PI3K/Akt and MAP kinase pathways, the Aktinhibitor IV (Akti IV) (Calbiochem, Darmstadt, Germany) and the MEKinhibitor U0126 (Sigma-Aldrich, St. Louis, Mo., USA) were added to theculture at the indicated time and concentrations, with dimethylsulphoxide (DMSO) as the vehicle and control.

Later work of third parties revealed that the KAT-10 cells which we usedare actually colon cancer cells derived from H29 cells. Schweppe R E,Klopper J P, Korch C, Pugazhenthi U, Benezra M, Knauf J A, Fagin J A,Marlow L A, Copland J A, Smallridge R C, Haugen B R. Deoxyribonucleicacid profiling analysis of 40 human thyroid cancer cell lines revealscross-contamination resulting in cell line redundancy andmisidentification. J Clin Endocrinol Metab. 2008 November;93(11):4331-41. Epub 2008 Aug. 19.

Lentivirus-mediated RNA Interference of Akt-1, Akt-2, and BRAF

The lentiviral pSicoR-PGK-GFP and pSicoR-PGK-puro vectors (Addgene Inc.Cambridge, Mass., USA) encoding hairpin RNA sequences were used toknock-down specific Akt-1, Akt-2 and BRAF. The hairpin sequences usedfor BRAF, Akt-1, Akt-2, and combined Akt-1 and Akt-2 (Akt-1/2) werepresented in Table 1. To generate lentiviral particles, human embryonickidey 293 cells (ATCC, Manassas, Va., USA) were co-transfected with thelentiviral vector and compatible packaging plasmid mixture usingLipofectamine 2000 (Invitrogen), following the manufacturer'sinstructions. NPA and KAT-10 cells were exposed to lentivirus-containingsupernatant for 16 hours in the presence of Polybrene (Sigma). After 3-4days, the cells were serum-starved (0.5% FBS) and harvested 24 hourslater in RIPA lysis buffer. Western blotting assays were performed todetect the protein expression of Akt-1, Akt-2, and BRAF.

Western Blotting Assay

Cells were lysed in RIPA buffer (Santa Cruz, Calif.). Cellular proteinswere resolved by electrophoresis on a SDS-polyacrylamide (10%) gel(SDS-PAGE), transferred onto PVDF membranes (Amersham Pharmacia Biotech,Piscataway, N.J.), and immunoblotted with specific primary antibodies.Anti-BRAF (Sc-166), anti-phospho-Akt-1/2/3 (Sc-7985-R), anti-phospho-ERK(Sc-7383), and anti-Actin (Sc-1616-R) were purchased from Santa Cruz(Santa Cruz, Calif.). Anti-Akt-1 (#2967) and anti-Akt-2 (#2964) werepurchased from Cell Signaling Technologies, Inc. (Beverly, Mass.).Antigen-antibody complexes were visualized using HRP-conjugatedanti-mouse (Sc-2005, Santa Cruz, Calif.) or anti-rabbit (Sc-2004, SantaCruz, Calif.) IgG antibodies and ECL Western Blotting Analysis System(Amersham Pharmacia).

Cell Proliferation Assay

Cells (800/well) were seeded into a 96-well plate and cultured with 2.5%FBS. MTT assay was performed daily over a 5-day time course to evaluatecell numbers using a MTT cell proliferation assay kit (ATCC, Manassas,Va., USA) following the manufacturer's instructions.

Colony Formation Assay

For soft-agar colony-formation assay, 1×10⁵ cells were plated into6-well plates with a bottom layer of 0.6% agar and a top layer of 0.3%agar. Following hardening of soft agar, plates were incubated at 37° C.with 5% CO₂. After 2-3 weeks of culture, colonies were counted andphotographed under a microscope.

Cell Invasion Assay

Cell invasion was assayed in triplicates using Matrigel-coated Transwellcell culture chambers (#354481, BD Biosciences) according to theinstructions of the manufacturer. Briefly, cells (1.5×10⁵ cells/well)suspended in serum-free medium were placed in the upper chamber of theTranswell insert, and RPMI 1640 medium containing 10% FBS was added tothe lower chamber. Following a 24h-incubation at 37° C. with 5% CO₂,non-invasive cells in the upper chamber were removed and invasive cellswere fixed in 100% methanol and stained with 0.5% crystal violet in 2%ethanol. The numbers of invasive cells were photographed and countedunder a microscope.

Cell Cycle Analysis

Cells were harvested, washed twice in PBS, and resuspended in 70%ethanol on ice for at least 30 min. After centrifugation, 1×10⁶ thyroidcancer cells transiently transected with various siRNA constructs wereresuspended in 1 ml of propidium iodide staining solution (50 μg ofpropidium iodide, 1 mg of RNase A, and 1 mg of glucose per 1 ml PBS) andincubated at room temperature for 30 min. Cell cycles were analyzedbased on DNA contents by FACS using a LSR Flow Cytometer (BDBiosciences, N.J.).

Apoptosis Assay

Thyroid cancer cells were transiently transfected with various siRNAconstructs. Cells were serum-starved for 24 h, followed by culture inmedium containing 10% FBS for 24 h as described (Yamane K, Tateishi K,Klose R J, et al. PLU-1 is an H3K4 demethylase involved intranscriptional repression and breast cancer cell proliferation. MolCell. 2007; 25:801-812). Cells were harvested, washed with PBS, andsubjected to sequential staining with Annexin V-PE Apoptosis DetectionKit (BD Biosciences) by two-color flow cytometry, according to themanufacturer's protocol. Cells that were Annexin V-positive and7-AAD-negative served as early apoptotic population. Cells that wereboth Annexin V- and 7-AAD-positive served as late apoptotic population.

Xenograft Tumor Assay in Nude Mice

Puromycin-selected and stably transfected cells were grown toapproximately 80-90% confluence and harvested with 0.25% Trypsin/1 mMEDTA solution. Five×10⁶ cells in 100 μl of RPMI 1640 medium wereinjected into the flanks of nude mice (five for each group) at the ageof about 5-week (Harlan Sprague Dawley, Indianapolis, Ind.). Tumorgrowth was evaluated by measuring the size of the tumor on the skinsurface and photographed twice a week. The tumor volume is calculated bythe formula “volume=(width)²×length/2,” as previously described (Gray MJ, Wey J S, Belcheva A, et al. Neuropilin-1 suppresses tumorigenicproperties in a human pancreatic adenocarcinoma cell line lackingneuropilin-1 coreceptors. Cancer Res. 2005; 65:3664-3670). At the end ofexperiment, mice were scarified, and the developed tumors weresurgically removed, weighted, and photographed.

RNA Extraction and Quantitative RT-PCR Analysis

Total RNA was isolated using TRIzol™ reagent according to theinstructions of the manufacturer (Invitrogen). Normal human thyroid RNAsamples purchased from Stratagene (La Jolla, Calif.) were used aspositive control. The reverse transcription synthesis of cDNA wasconducted with the SuperScript First-Strand Synthesis kit (Invitrogen),following the manufacturer's instruction. Quantitative real-time PCRanalysis was performed to evaluate expression of thyroid genes on an ABIPrism 7900HT Sequence Detector (Applied Biosystems), using SYBR GreenPCR Core Reagents kit according to the instructions of the manufacturer(Applied Biosystems). The expression value of each gene was normalizedto the amount of β-actin cDNA to calculate the relative amount of RNApresent in each sample. The primers of intron-spanning thyroid-specificgenes, Tg, TSHR, NIS, TTF1 and TTF2, were designed using Primer Express(Applied Biosystems, CA) and presented in Table 2. A semi-quantitativeRT-PCR amplification was also carried out to amplify hNIS, using theprimers 5′-TCC ATG TAT GGC GTG AAC C-3′ (forward; SEQ ID NO: 1) and5′-CTT CGA AGA TGT CCA GCA CC-3′ (reverse; SEQ ID NO: 2). The β-actingene was run in parallel for quality control, using the primers 5′-TCTACA ATG AGC TGC GTG TG-3′ (forward; SEQ ID NO: 3) and 5′-TAG ATG GGC ACAGTG TGG GT-3′ (reverse; SEQ ID NO: 4). PCR products were resolved by1.5% agarose gel electrophoresis and visualized by ethidium bromidestaining.

Flow Cytometry Analysis of hNIS Expression

Thyroid cancer cells treated with specific inhibitors and various siRNAconstructs to induce the expression of NIS were incubated with VJ2 α-NISmAb (a gift from Dr. Sabine Costagliola at the Free University ofBrussels) (Pohlenz J, Duprez L, Weiss R E, Vassart G, Refetoff S,Costagliola S. Failure of membrane targeting causes the functionaldefect of two mutant sodium iodide symporters. J Clin Endocrinol Metab.2000; 85:2366-2369) diluted at 1:20 in FACS buffer (3% FBS, 0.02% NaN₃in PBS) at 4° C. for 1 h. Cells were then washed once with FACS bufferand incubated with FITC-conjugated α-mouse IgG (Sigma) diluted at 1:100in FACS buffer at 4° C. for 1 h. Cells were washed again in FACS buffer,resuspended in 2 ml of FACS buffer with 7-AAD, and analyzed by FACSusing a LSR Flow Cytometer (BD Biosciences, N.J.). Secondary antibodyalone was used as a negative control. Fluorescent microscopicexamination was conducted to monitor NIS expression (Nikon Corporation,Tokyo, Japan).

Radioactive Iodide Uptake (RAIU) Assay

Thyroid cancer cells (1×10⁶ cells/well) treated under the indicatedconditions were seeded in 12-well plates. Cells in 0.5 ml/well wereincubated with RPMI 1640 medium containing 1 μCi Na¹²⁵I and 5 μMnon-radioactive NaI for 1 h at 37° C. with 5% CO₂. Subsequently, themedium was aspirated and cells were quickly washed twice with ice-coldHank's balanced salt solution (HBSS) and harvested with tripsin-EDTA.Cells were collected and radioactivity was counted by a gamma-counter.

Statistical Analysis

Except for the animal studies, all the experiments were similarly doneat least three times. Statistical analysis for pair comparison wasperformed using t-test.

REFERENCES

The disclosure of each reference cited is expressly incorporated herein.

-   1. Jemal A, Devesa S S, Hartge P, Tucker M A. Recent trends in    cutaneous melanoma incidence among whites in the United States. J    Natl Cancer Inst 2001; 93:678-83.-   2. Lasithiotakis K G, Leiter U, Gorkievicz R, et al. The incidence    and mortality of cutaneous melanoma in Southern Germany: trends by    anatomic site and pathologic characteristics, 1976 to 2003. Cancer    2006; 107:1331-9.-   3. Ries L A G, Melbert D, Krapcho M, et al.(eds). SEER Cancer    Statistics Review, 1975-2005, National Cancer Institute. Bethesda,    Md., http://seer.cancer.gov/csr/1975_2005/, based on November 2007    SEER data submission, posted to the SEER web site, 2008.-   4. Flaherty K T. Chemotherapy and targeted therapy combinations in    advanced melanoma. Clin Cancer Res 2006; 12:2366s-70s.-   5. Tawbi H A, Kirkwood J M. Management of metastatic melanoma. Semin    Oncol 2007; 34:532-45.-   6. Davies H, Bignell G R, Cox C, et al. Mutations of the BRAF gene    in human cancer. Nature 2002; 417:949-54.-   7. Wu H, Goel V, Haluska F G. PTEN signaling pathways in melanoma.    Oncogene 2003 22:3113-22.-   8. Curtin J A, Fridlyand J, Kageshita T, et al. Distinct sets of    genetic alterations in melanoma. N Engl J Med 2005; 353:2135-47.-   9. Marquette A, Bagot M, Bensussan A, Dumaz N. Recent discoveries in    the genetics of melanoma and their therapeutic implications. Arch    Immunol Ther Exp (Warsz) 2007; 55:363-72.-   10. Satyamoorthy K, Li G, Gerrero M R, et al. Constitutive    mitogen-activated protein kinase activation in melanoma is mediated    by both BRAF mutations and autocrine growth factor stimulation.    Cancer Res 2003; 63:756-9.-   11. Stahl J M, Sharma A, Cheung M, et al. Deregulated Akt3 activity    promotes development of malignant melanoma. Cancer Res 2004;    64:7002-10.-   12. Dai D L, Martinka M, Li G. Prognostic significance of activated    Akt expression in melanoma: a clinicopathologic study of 292 cases.    J Clin Oncol 2005; 23:1473-82.-   13. Meier F, Schittek B, Busch S, et al. The RAS/RAF/MEK/ERK and    PI3K/AKT signaling pathways present molecular targets for the    effective treatment of advanced melanoma. Front Biosci 2005;    10:2986-3001.-   14. Meier F, Busch S, Lasithiotakis K, et al. Combined targeting of    MAPK and AKT signalling pathways is a promising strategy for    melanoma treatment. Br J Dermatol 2007; 156:1204-13.-   15. Kwong L, Chin L, Wagner S N. Growth factors and oncogenes as    targets in melanoma: lost in translation? Adv Dermatol 2007;    23:99-129.-   16. Faivre J, Clerc J, Gérolami R, et al. Long-term radioiodine    retention and regression of liver cancer after sodium iodide    symporter gene transfer in Wistar rats. Cancer Res 2004; 64:8045-51.-   17. Dwyer R M, Bergert E R, O'connor M K, et al. In vivo radioiodide    imaging and treatment of breast cancer xenografts after MUC1-driven    expression of the sodium iodide symporter. Clin Cancer Res 2005;    11:1483-9.-   18. Riesco-Eizaguirre G, Santisteban P. A perspective view of sodium    iodide symporter research and its clinical implications. Eur J    Endocrinol 2006; 155:495-512.-   19. Schipper M L, Riese C G, Seitz S, et al. Efficacy of 99mTc    pertechnetate and 131I radioisotope therapy in sodium/iodide    symporter (NIS)-expressing neuroendocrine tumors in vivo. Eur J Nucl    Med Mol Imaging 2007; 34:638-50.-   20. Willhauck M J, Sharif Samani B R, Klutz K, et al.    Alpha-fetoprotein promoter-targeted sodium iodide symporter gene    therapy of hepatocellular carcinoma. Gene Ther 2008; 15:214-23.-   21. Nilsson M. Iodide handling by the thyroid epithelial cell. Exp    Clin Endocrinol Diabetes 2001; 109:13-17.-   22. Mian C, Lacroix L, Bidart J.-M, Caillou B, Filetti S,    Schlumberger M. Sodium/iodide symporter in thyroid cancer. Exp Clin    Endocrinol Diabetes 2001; 109: 47-51.-   23. Duntas L H, Cooper D S. Review on the occasion of a decade of    recombinant human TSH: prospects and novel uses. Thyroid 2008;    18(5):509-16.-   24. Xing M, Westra W H, Tufano R P, et al. BRAF mutation predicts a    poorer clinical prognosis for papillary thyroid cancer. J Clin    Endocrinol Metab 2005; 90:6373-9.-   25. Riesco-Eizaguirre G, Gutierrez-Martinez P, Garcia-Cabezas MA,    Nistal M, Santisteban P. The oncogene BRAF V600E is associated with    a high risk of recurrence and less differentiated papillary thyroid    carcinoma due to the impairment of Na+/I− targeting to the membrane.    Endocr Relat Cancer 2006; 13:257-69.-   26. Mian C, Barollo S, Pennelli G, et al. Molecular characteristics    in papillary thyroid cancers (PTCs) with no (131)I uptake. Clin    Endocrinol 2008; 68:108-16.-   27. Durante C, Puxeddu E, Ferretti E, et al. BRAF mutations in    papillary thyroid carcinomas inhibit genes involved in iodine    metabolism. J Clin Endocrinol Metab 2007; 92:2840-3.-   28. Giordano T J, Kuick R, Thomas D G, et al. Molecular    classification of papillary thyroid carcinoma: distinct BRAF, RAS,    and RET/PTC mutation-specific gene expression profiles discovered by    DNA microarray analysis. Oncogene 2005; 24:6646-56.-   29. Di Cristofaro J, Silvy M, Lanteaume A, Marcy M, Carayon P, De    Micco C. Expression of tpo mRNA in thyroid tumors: quantitative PCR    analysis and correlation with alterations of ret, Braf, ras and pax8    genes. Endocr Relat Cancer 2006; 13:485-95.-   30. Cass L A, Meinkoth J L. Ras signaling through PI3K confers    hormone-independent proliferation that is compatible with    differentiation. Oncogene. 2000; 19:924-32.-   31. Garcia B, Santisteban P. PI3K is involved in the IGF-I    inhibition of TSH-induced sodium/iodide symporter gene expression.    Mol Endocrinol 2002; 16:342-52.-   32. Friday B B and Adjei A A. Advances in targeting the    Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK    inhibitors for cancer therapy. Clin Cancer Res 2008; 14:342-6.-   33. Ellerhorst J A, Sendi-Naderi A, Johnson M K, Cooke C P, Dang S    M, Diwan A H. Human melanoma cells express functional receptors for    thyroid-stimulating hormone. Endocr Relat Cancer 2006; 13:1269-77.-   34. Fagin J A, Matsuo K, Karmakar A, Chen D L, Tang S H, Koeffler    H P. High prevalence of mutations of the p53 gene in poorly    differentiated human thyroid carcinomas. J Clin Invest 1993;    91:179-84.-   35. Schweppe R E, Klopper J P, Korch C, Pugazhenthi U, Benezra M,    KnaufJA, et al. DNA profiling analysis of 40 human thyroid cancer    cell lines reveals cross-contamination resulting in cell line    redundancy and minidentification. J Clin Endocrinol Metab 2008    Aug. 19. [Epub ahead of print]-   36. He S J, Stevens G, Braithwaite A W, Eccles M R. Transfection of    melanoma cells with antisense PAX3 oligonucleotides additively    complements cisplatin-induced cytotoxicity. Mol Cancer Ther 2005;    4:996-1003.-   37. Pohlenz J, Duprez L, Weiss R E, Vassart G, Refetoff S,    Costagliola S. Failure of membrane targeting causes the functional    defect of two mutant sodium iodide symporters. J Clin Endocrinol    Metab 2000; 85:2366-9.-   38. Kau T R, Schroeder F, Ramaswamy S, et al. A chemical genetic    screen identifies inhibitors of regulated nuclear export of a    Forkhead transcription factor in PTEN-deficient tumor cells. Cancer    Cell 2003; 4:463-76.-   39. Liu D, Liu Z, Condouris S, Xing M. BRAF V600E maintains    proliferation, transformation, and tumorigenicity of BRAF-mutant    papillary thyroid cancer cells. J Clin Endocrinol Metab 2007;    92:2264-71.-   40. Ball D W, Jin N, Rosen D M, et al. Selective growth inhibition    in BRAF mutant thyroid cancer by the mitogen-activated protein    kinase kinase 1/2 inhibitor AZD6244. J Clin Endocrinol Metab 2007;    92:4712-8.-   41. Boisvert-Adamo K, Aplin A E. B-RAF and PI-3 kinase signaling    protect melanoma cells from anoikis. Oncogene 2006; 25:4848-56.-   42. Mazzaferri E L: An overview of the management of thyroid cancer.    In: Mazzaferri E L, Harmer C, Mallick U K, Kendall-Taylor P, eds.    Practical Management of Thyroid Cancer: A Multidisciplinary    Approach. London, England: Springer-Verlag 1-28,2006.-   43. Cooper D S, Doherty G M, Haugen B R, et al. The American Thyroid    Association Guidelines Taskforce. Management guidelines for patients    with thyroid nodules and differentiated thyroid cancer. Thyroid    2006; 16:109-42.-   44. Xing M. BRAF mutation in papillary thyroid cancer: pathogenic    role, molecular bases, and clinical implications. Endocr Rev 2007;    28:742-62.-   45. Baker C H, Morris J C. The sodium-iodide symporter. Curr Drug    Targets Immune Endocr Metabol Disord 2004; 4:167-74.-   46. Buchsbaum D J, Chaudhuri T R, Zinn K R. Radiotargeted gene    therapy. J Nucl Med 2005; 46 Suppl 1:179S-86S.

1. A method of treating a human cancer in a patient comprising:administering an inhibitor of a PI3K/Akt pathway protein or itsexpression to the patient; and administering an inhibitor of a MAPkinase pathway protein or its expression to the patient, wherein theinhibitors are administered in sufficient amounts to induce expressionof one or more iodide-handling genes in the human cancer.
 2. The methodof claim 1 further comprising: administering radioiodine to the patient.3. (canceled)
 4. The method of claim 2 wherein the radioiodine isadministered subsequent to the administering of the inhibitors.
 5. Themethod of claim 1 wherein the human cancer is a thyroid tumor.
 6. Themethod of claim 1 wherein the human cancer is a melanoma.
 7. The methodof claim 1 wherein the human cancer is a non-thyroid tumor.
 8. Themethod of claim 1 wherein the cancer has an activating mutation in thePI3K/Akt pathway.
 9. The method of claim 8 wherein the mutation isselected from the group consisting of PIK3CA mutation, PIK3D mutation,PIK3B mutation, Ras mutation, PTEN mutation, and PI3KCA amplification.10. The method of claim 8 wherein the mutation is in a receptor tyrosinekinase gene.
 11. The method of claim 1 wherein the cancer has anactivating mutation in the MAP kinase pathway.
 12. The method of claim11 wherein the cancer has an activating mutation selected from the groupconsisting of: BRAF mutation, RET/PTC rearrangement, Ras mutation, MEKmutation, and ERK mutation.
 13. The method of claim 1 wherein the cancerhas an activating mutation in PI3K.
 14. The method of claim 1 whereinthe cancer has an activating mutation in MAP kinase.
 15. The method ofclaim 1 wherein the cancer has activating mutations in both PI3K/Akt andMAP kinase pathways.
 16. The method of claim 1 wherein the cancer is apoorly differentiated or undifferentiated thyroid tumor.
 17. The methodof claim 2 wherein prior to administration of the inhibitors, the canceris non-responsive to radioiodine treatment.
 18. The method of claim 1wherein a thyroid stimulating hormone is administered to the patient inan amount sufficient to induce expression of one or more iodide-handlinggenes in the cancer.
 19. The method of claim 1 wherein a PI3K/Aktpathway protein inhibitor is administered which is selected from thegroup consisting of perifosine, triciribine, temsirolimus, everolimus,motesanib, axitinib, sunitinib, Wortmanin, LYS 294002, and AktiIV. 20.The method of claim 1 wherein a MAP kinase pathway protein inhibitor isadministered which is selected from the group consisting of CI-1040,PD325901, PD184352, AZD6344, ARRY-142886, RDEA119, RDEA436, RDEA119,PLX4720, BAY43-9006 (sorafenib) and U0126.
 21. The method of claim 1wherein a PI3K/Akt pathway expression inhibitor is administered which issiRNA.
 22. The method of claim 1 wherein a MAP kinase pathway expressioninhibitor is administered which is siRNA.
 23. The method of claim 1wherein the cancer is selected from the group consisting of salivary,lacrimal, stomach, colon, liver, and breast cancer.
 24. The method ofclaim 1 wherein a MAP kinase pathway expression inhibitor isadministered which is selected from the group of siRNA consisting ofRas, RAF, MEK1, MEK2, ERK1, and ERK2 siRNA.
 25. The method of claim 1wherein the one or more iodide-handling genes are selected from thegroup consisting of the sodium/iodide symporter, thyroid stimulatinghormone receptor, thyroglobulin, thyroperoxidase, pendrin, and thyroidtranscription factors TTF-1, TTF-2, and PAX8.
 26. A method of treating amelanoma or thyroid cancer in a human comprising: administering aninhibitor of a PI3K/Akt pathway protein or its expression and aninhibitor of a MAP kinase pathway protein or its expression to thepatient in sufficient amounts to induce expression of one or moreiodide-handling genes in the melanoma or thyroid cancer; andadministering radioiodine to the human.
 27. (canceled)